ticker,rpa_date_utc,rpa_time_utc,rp_entity_id,entity_name,relevance,event_sentiment_score,group,sub_type,event_text,news_type,source_name,headline
VRTX,2024-01-02,15:36:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-04,21:21:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-10,21:07:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel) For The Treatment Of Transfusion-Dependent Beta Thalassemia >VRTX
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Business Wire,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:24:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:37:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-16,19:52:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-18,14:00:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?"
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to Submit a New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to Submit a New Drug Application to FDA by Mid-2024 >VRTX
VRTX,2024-01-30,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024 -- WSJ
VRTX,2024-01-30,11:30:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company is also testing the same medicine in,FULL-ARTICLE,Dow Jones Newswires,Vertex Unveils Strong Data on Opioid Alternative -- Barrons.com
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,16:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex's Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst. VRTX Stock Slips, Bounces Back. -- IBD"
VRTX,2024-01-30,18:13:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-30,21:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-31,15:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan
VRTX,2024-02-02,11:37:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein
VRTX,2024-02-05,14:31:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?"
VRTX,2024-02-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.71,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.71 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $4.20,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $4.20 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $968.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $968.8M >VRTX
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -5-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2024-02-05,21:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev Guidance of $10.55B to $10.75B >VRTX
VRTX,2024-02-05,21:20:24,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.20 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,22:00:04,57CAAB,Vertex Pharmaceuticals Inc.,96,0.62,products-services,positive,Vertex Pharmaceuticals unveiled promising Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital
VRTX,2024-02-06,16:24:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-02-06,16:24:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan
VRTX,2024-02-12,14:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,16:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,17:45:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,18:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,18:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:10:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:28:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:47:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:50:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:55:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:58:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,738 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:04:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:18:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:34:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 314 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,22:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:07:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,22:15:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-15,11:36:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research
VRTX,2024-02-15,16:21:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-16,21:09:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-19,08:00:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)"
VRTX,2024-02-20,15:24:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,15:24:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,15:33:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:00:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,16:33:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-20,21:07:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-21,14:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,14:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:21:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:48:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,15:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,16:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:24:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:30:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,21:42:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,22:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:51:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:56:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,23:00:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Kalydeco for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,21:12:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:14:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:28:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:32:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 360 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,15:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:54:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,16:15:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,16:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,18:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:36:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,21:42:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:52:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:05:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:09:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:47:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:59:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,23:08:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-03-21,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) >VRTX
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1 Study in,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1 Study in Healthy Volunteers This Month >VRTX
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces New Drug Submission for Exagamglogene Autotemcel Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:01:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Gets Health Canada Priority Review of Exa-cel,NEWS-FLASH,Dow Jones Newswires,"Vertex Gets Health Canada Priority Review of Exa-cel in Sickle-Cell Diseas, Transfusion-Dependent Beta Thalassemia"
VRTX,2024-04-03,20:04:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 240 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 240 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Will Acquire Alpine for $65,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Will Acquire Alpine for $65 Per Shr or About $4.9 B in Cash >VRTX ALPN
VRTX,2024-04-10,20:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,interest,Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk,NEWS-FLASH,Dow Jones Newswires,Vertex Subsidiary of Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:15:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B
VRTX,2024-04-10,20:30:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,20:39:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:25:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:40:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,08:50:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ"
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group
VRTX,2024-04-11,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,VC Health Pulse: Magenta Medical Advances New Heart-Pump Technology; Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,William Blair has an outperform rating on Vertex,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,20:18:48,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He reiterated his buy rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD
VRTX,2024-04-12,16:12:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-04-15,12:03:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.66,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS
VRTX,2024-04-18,11:54:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-04-18,11:54:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:59:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex is also set to launch Phase 3 trials,FULL-ARTICLE,MarketWatch,MW Vertex's stock climbs as non-opioid pain treatment advances
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,13:44:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-23,13:59:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-26,15:43:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Announces European Commission Approval for Kalydeco to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-05-02,14:09:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-03,20:12:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -4-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $4.21,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX
VRTX,2024-05-06,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $1.1B >VRTX
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -4-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:03:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX
VRTX,2024-05-06,20:03:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: the company reported adjusted earnings of $4.76 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Factset expected Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex stock analysts projected $16.52 earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-14,17:14:38,57CAAB,Vertex Pharmaceuticals Inc.,98,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock -- IBD
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals posted rising EPS,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-15,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Business Wire,Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Names Jennifer Schneider to Board,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Names Jennifer Schneider to Board >VRTX
VRTX,2024-05-15,15:45:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,15:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,16:24:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 54 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:26:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 32 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-19,07:00:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)"
VRTX,2024-05-20,12:36:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-05-20,19:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,17:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,20:23:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,17:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:14:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:28:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,unchanged,Vertex reiterated its 2024 outlook for sales,FULL-ARTICLE,Dow Jones Newswires,New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout -- IBD
VRTX,2024-05-28,15:30:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,14:09:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,20:11:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,15:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,20:09:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital
VRTX,2024-05-31,15:00:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,20:21:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:10:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:14:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic -2-
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the -2-
VRTX,2024-06-07,20:09:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital
VRTX,2024-06-12,14:00:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-12,14:00:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:12:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo
VRTX,2024-06-26,14:27:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic
VRTX,2024-06-27,20:06:49,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-06-28,20:05:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance Of New Drug Application For Vanzacaftor,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Acceptance Of New Drug Application For Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment For Cystic Fibrosis >VRTX"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-10,14:33:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley
VRTX,2024-07-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA >VRTX
VRTX,2024-07-15,20:50:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-15,21:05:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-16,13:15:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: the company's collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX,PRESS-RELEASE,PR Newswire,Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald
VRTX,2024-07-22,17:18:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen
VRTX,2024-07-24,16:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-24,20:07:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-25,20:07:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Business Wire,Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:11:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: FDA Grants Priority Review and Assigns a PDUFA Target Action Date of Jan. 30
VRTX,2024-07-30,17:27:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,17:42:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,19:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity
VRTX,2024-08-01,19:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss/Shr $13.92,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss/Shr $13.92 >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss $3.59B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss $3.59B >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -5-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -5-
VRTX,2024-08-01,20:02:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX
VRTX,2024-08-01,20:02:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX
VRTX,2024-08-01,20:10:41,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook -- IBD
VRTX,2024-08-01,20:18:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim
VRTX,2024-08-02,20:13:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
VRTX,2024-08-05,14:29:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.
VRTX,2024-08-07,13:54:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,15:51:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-12,20:09:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-19,07:00:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)"
VRTX,2024-08-21,07:12:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Alpine Immune Sciences Inc, Inst Holders, 2Q 2024 (ALPN)",RNS-SEC13F,Dow Jones Newswires,"Alpine Immune Sciences  Inc, Inst Holders, 2Q 2024 (ALPN)"
VRTX,2024-08-30,20:27:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-30,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:20:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-09-25,20:22:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-25,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of -3-
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral -3-
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley
VRTX,2024-10-02,14:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-03,20:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 999 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.32,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS
VRTX,2024-10-18,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Business Wire,"Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-18,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney -2-
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on -2-
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.38,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.05B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.05B >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -5-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -5-
VRTX,2024-11-04,21:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Beats Third-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Beats Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex expects to launch a next-generation treatment,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,earnings,above-expectations,Vertex Pharmaceuticals beat Wall Street's third-quarter expectations,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,"During the third quarter, Vertex's sales climbed 12% to $2.77 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
VRTX,2024-11-08,20:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,14:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,21:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-13,21:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Citigroup
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup
VRTX,2024-11-15,15:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-11-19,08:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)"
VRTX,2024-11-19,21:11:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 15 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Business Wire,Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-08,17:52:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies
VRTX,2024-12-10,12:21:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,products-services,negative,Cervomed Phase 2b Study of Neflamapimod Misses,FULL-ARTICLE,Dow Jones Newswires,CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results From Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of -2-
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint >VRTX
VRTX,2024-12-19,15:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,GlobeNewswire,Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.
VRTX,2024-12-20,13:00:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals to report adjusted earnings of $4.05 per share,FULL-ARTICLE,Dow Jones Newswires,Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? -- IBD
VRTX,2024-12-20,13:45:25,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays
VRTX,2024-12-20,20:35:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) To Include Additional Non-F508del TRIKAFTA-Responsive Variants >VRTX
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA -2-
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,21:00:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:09:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,21:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:24:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,23:16:36,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock -- IBD
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities
VRTX,2024-12-23,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Business Wire,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-12-23,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-01-02,15:36:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-04,21:21:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-10,21:07:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel) For The Treatment Of Transfusion-Dependent Beta Thalassemia >VRTX
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Business Wire,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:24:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:37:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-16,19:52:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-18,14:00:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?"
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to Submit a New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to Submit a New Drug Application to FDA by Mid-2024 >VRTX
VRTX,2024-01-30,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024 -- WSJ
VRTX,2024-01-30,11:30:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company is also testing the same medicine in,FULL-ARTICLE,Dow Jones Newswires,Vertex Unveils Strong Data on Opioid Alternative -- Barrons.com
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,16:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex's Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst. VRTX Stock Slips, Bounces Back. -- IBD"
VRTX,2024-01-30,18:13:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-30,21:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-31,15:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan
VRTX,2024-02-02,11:37:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein
VRTX,2024-02-05,14:31:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?"
VRTX,2024-02-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.71,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.71 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $4.20,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $4.20 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $968.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $968.8M >VRTX
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -5-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2024-02-05,21:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev Guidance of $10.55B to $10.75B >VRTX
VRTX,2024-02-05,21:20:24,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.20 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,22:00:04,57CAAB,Vertex Pharmaceuticals Inc.,96,0.62,products-services,positive,Vertex Pharmaceuticals unveiled promising Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital
VRTX,2024-02-06,16:24:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-02-06,16:24:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan
VRTX,2024-02-12,14:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,16:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,17:45:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,18:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,18:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:10:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:28:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:47:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:50:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:55:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:58:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,738 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:04:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:18:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:34:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 314 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,22:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:07:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,22:15:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-15,11:36:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research
VRTX,2024-02-15,16:21:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-16,21:09:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-19,08:00:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)"
VRTX,2024-02-20,15:24:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,15:24:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,15:33:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:00:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,16:33:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-20,21:07:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-21,14:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,14:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:21:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:48:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,15:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,16:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:24:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:30:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,21:42:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,22:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:51:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:56:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,23:00:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Kalydeco for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,21:12:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:14:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:28:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:32:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 360 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,15:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:54:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,16:15:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,16:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,18:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:36:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,21:42:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:52:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:05:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:09:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:47:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:59:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,23:08:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-03-21,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) >VRTX
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1 Study in,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1 Study in Healthy Volunteers This Month >VRTX
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces New Drug Submission for Exagamglogene Autotemcel Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:01:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Gets Health Canada Priority Review of Exa-cel,NEWS-FLASH,Dow Jones Newswires,"Vertex Gets Health Canada Priority Review of Exa-cel in Sickle-Cell Diseas, Transfusion-Dependent Beta Thalassemia"
VRTX,2024-04-03,20:04:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 240 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 240 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Will Acquire Alpine for $65,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Will Acquire Alpine for $65 Per Shr or About $4.9 B in Cash >VRTX ALPN
VRTX,2024-04-10,20:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,interest,Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk,NEWS-FLASH,Dow Jones Newswires,Vertex Subsidiary of Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:15:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B
VRTX,2024-04-10,20:30:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,20:39:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:25:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:40:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,08:50:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ"
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group
VRTX,2024-04-11,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,VC Health Pulse: Magenta Medical Advances New Heart-Pump Technology; Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,William Blair has an outperform rating on Vertex,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,20:18:48,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He reiterated his buy rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD
VRTX,2024-04-12,16:12:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-04-15,12:03:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.66,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS
VRTX,2024-04-18,11:54:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-04-18,11:54:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:59:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex is also set to launch Phase 3 trials,FULL-ARTICLE,MarketWatch,MW Vertex's stock climbs as non-opioid pain treatment advances
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,13:44:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-23,13:59:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-26,15:43:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Announces European Commission Approval for Kalydeco to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-05-02,14:09:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-03,20:12:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -4-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $4.21,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX
VRTX,2024-05-06,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $1.1B >VRTX
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -4-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:03:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX
VRTX,2024-05-06,20:03:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: the company reported adjusted earnings of $4.76 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Factset expected Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex stock analysts projected $16.52 earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-14,17:14:38,57CAAB,Vertex Pharmaceuticals Inc.,98,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock -- IBD
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals posted rising EPS,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-15,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Business Wire,Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Names Jennifer Schneider to Board,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Names Jennifer Schneider to Board >VRTX
VRTX,2024-05-15,15:45:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,15:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,16:24:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 54 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:26:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 32 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-19,07:00:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)"
VRTX,2024-05-20,12:36:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-05-20,19:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,17:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,20:23:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,17:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:14:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:28:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,unchanged,Vertex reiterated its 2024 outlook for sales,FULL-ARTICLE,Dow Jones Newswires,New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout -- IBD
VRTX,2024-05-28,15:30:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,14:09:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,20:11:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,15:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,20:09:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital
VRTX,2024-05-31,15:00:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,20:21:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:10:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:14:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic -2-
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the -2-
VRTX,2024-06-07,20:09:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital
VRTX,2024-06-12,14:00:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-12,14:00:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:12:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo
VRTX,2024-06-26,14:27:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic
VRTX,2024-06-27,20:06:49,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-06-28,20:05:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance Of New Drug Application For Vanzacaftor,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Acceptance Of New Drug Application For Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment For Cystic Fibrosis >VRTX"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-10,14:33:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley
VRTX,2024-07-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA >VRTX
VRTX,2024-07-15,20:50:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-15,21:05:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-16,13:15:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: the company's collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX,PRESS-RELEASE,PR Newswire,Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald
VRTX,2024-07-22,17:18:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen
VRTX,2024-07-24,16:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-24,20:07:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-25,20:07:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Business Wire,Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:11:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: FDA Grants Priority Review and Assigns a PDUFA Target Action Date of Jan. 30
VRTX,2024-07-30,17:27:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,17:42:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,19:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity
VRTX,2024-08-01,19:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss/Shr $13.92,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss/Shr $13.92 >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss $3.59B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss $3.59B >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -5-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -5-
VRTX,2024-08-01,20:02:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX
VRTX,2024-08-01,20:02:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX
VRTX,2024-08-01,20:10:41,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook -- IBD
VRTX,2024-08-01,20:18:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim
VRTX,2024-08-02,20:13:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
VRTX,2024-08-05,14:29:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.
VRTX,2024-08-07,13:54:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,15:51:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-12,20:09:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-19,07:00:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)"
VRTX,2024-08-21,07:12:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Alpine Immune Sciences Inc, Inst Holders, 2Q 2024 (ALPN)",RNS-SEC13F,Dow Jones Newswires,"Alpine Immune Sciences  Inc, Inst Holders, 2Q 2024 (ALPN)"
VRTX,2024-08-30,20:27:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-30,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:20:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-09-25,20:22:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-25,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of -3-
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral -3-
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley
VRTX,2024-10-02,14:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-03,20:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 999 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.32,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS
VRTX,2024-10-18,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Business Wire,"Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-18,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney -2-
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on -2-
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.38,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.05B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.05B >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -5-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -5-
VRTX,2024-11-04,21:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Beats Third-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Beats Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex expects to launch a next-generation treatment,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,earnings,above-expectations,Vertex Pharmaceuticals beat Wall Street's third-quarter expectations,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,"During the third quarter, Vertex's sales climbed 12% to $2.77 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
VRTX,2024-11-08,20:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,14:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,21:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-13,21:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Citigroup
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup
VRTX,2024-11-15,15:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-11-19,08:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)"
VRTX,2024-11-19,21:11:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 15 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Business Wire,Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-08,17:52:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies
VRTX,2024-12-10,12:21:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,products-services,negative,Cervomed Phase 2b Study of Neflamapimod Misses,FULL-ARTICLE,Dow Jones Newswires,CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results From Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of -2-
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint >VRTX
VRTX,2024-12-19,15:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,GlobeNewswire,Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.
VRTX,2024-12-20,13:00:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals to report adjusted earnings of $4.05 per share,FULL-ARTICLE,Dow Jones Newswires,Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? -- IBD
VRTX,2024-12-20,13:45:25,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays
VRTX,2024-12-20,20:35:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) To Include Additional Non-F508del TRIKAFTA-Responsive Variants >VRTX
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA -2-
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,21:00:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:09:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,21:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:24:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,23:16:36,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock -- IBD
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities
VRTX,2024-12-23,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Business Wire,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-12-23,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-01-02,15:36:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-04,21:21:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-10,21:07:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel) For The Treatment Of Transfusion-Dependent Beta Thalassemia >VRTX
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Business Wire,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:24:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:37:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-16,19:52:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-18,14:00:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?"
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to Submit a New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to Submit a New Drug Application to FDA by Mid-2024 >VRTX
VRTX,2024-01-30,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024 -- WSJ
VRTX,2024-01-30,11:30:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company is also testing the same medicine in,FULL-ARTICLE,Dow Jones Newswires,Vertex Unveils Strong Data on Opioid Alternative -- Barrons.com
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,16:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex's Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst. VRTX Stock Slips, Bounces Back. -- IBD"
VRTX,2024-01-30,18:13:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-30,21:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-31,15:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan
VRTX,2024-02-02,11:37:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein
VRTX,2024-02-05,14:31:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?"
VRTX,2024-02-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.71,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.71 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $4.20,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $4.20 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $968.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $968.8M >VRTX
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -5-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2024-02-05,21:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev Guidance of $10.55B to $10.75B >VRTX
VRTX,2024-02-05,21:20:24,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.20 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,22:00:04,57CAAB,Vertex Pharmaceuticals Inc.,96,0.62,products-services,positive,Vertex Pharmaceuticals unveiled promising Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital
VRTX,2024-02-06,16:24:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-02-06,16:24:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan
VRTX,2024-02-12,14:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,16:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,17:45:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,18:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,18:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:10:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:28:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:47:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:50:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:55:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:58:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,738 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:04:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:18:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:34:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 314 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,22:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:07:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,22:15:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-15,11:36:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research
VRTX,2024-02-15,16:21:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-16,21:09:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-19,08:00:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)"
VRTX,2024-02-20,15:24:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,15:24:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,15:33:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:00:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,16:33:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-20,21:07:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-21,14:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,14:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:21:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:48:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,15:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,16:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:24:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:30:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,21:42:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,22:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:51:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:56:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,23:00:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Kalydeco for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,21:12:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:14:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:28:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:32:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 360 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,15:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:54:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,16:15:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,16:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,18:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:36:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,21:42:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:52:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:05:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:09:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:47:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:59:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,23:08:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-03-21,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) >VRTX
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1 Study in,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1 Study in Healthy Volunteers This Month >VRTX
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces New Drug Submission for Exagamglogene Autotemcel Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:01:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Gets Health Canada Priority Review of Exa-cel,NEWS-FLASH,Dow Jones Newswires,"Vertex Gets Health Canada Priority Review of Exa-cel in Sickle-Cell Diseas, Transfusion-Dependent Beta Thalassemia"
VRTX,2024-04-03,20:04:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 240 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 240 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Will Acquire Alpine for $65,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Will Acquire Alpine for $65 Per Shr or About $4.9 B in Cash >VRTX ALPN
VRTX,2024-04-10,20:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,interest,Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk,NEWS-FLASH,Dow Jones Newswires,Vertex Subsidiary of Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:15:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B
VRTX,2024-04-10,20:30:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,20:39:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:25:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:40:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,08:50:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ"
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group
VRTX,2024-04-11,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,VC Health Pulse: Magenta Medical Advances New Heart-Pump Technology; Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,William Blair has an outperform rating on Vertex,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,20:18:48,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He reiterated his buy rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD
VRTX,2024-04-12,16:12:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-04-15,12:03:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.66,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS
VRTX,2024-04-18,11:54:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-04-18,11:54:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:59:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex is also set to launch Phase 3 trials,FULL-ARTICLE,MarketWatch,MW Vertex's stock climbs as non-opioid pain treatment advances
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,13:44:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-23,13:59:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-26,15:43:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Announces European Commission Approval for Kalydeco to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-05-02,14:09:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-03,20:12:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -4-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $4.21,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX
VRTX,2024-05-06,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $1.1B >VRTX
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -4-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:03:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX
VRTX,2024-05-06,20:03:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: the company reported adjusted earnings of $4.76 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Factset expected Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex stock analysts projected $16.52 earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-14,17:14:38,57CAAB,Vertex Pharmaceuticals Inc.,98,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock -- IBD
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals posted rising EPS,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-15,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Business Wire,Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Names Jennifer Schneider to Board,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Names Jennifer Schneider to Board >VRTX
VRTX,2024-05-15,15:45:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,15:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,16:24:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 54 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:26:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 32 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-19,07:00:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)"
VRTX,2024-05-20,12:36:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-05-20,19:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,17:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,20:23:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,17:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:14:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:28:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,unchanged,Vertex reiterated its 2024 outlook for sales,FULL-ARTICLE,Dow Jones Newswires,New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout -- IBD
VRTX,2024-05-28,15:30:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,14:09:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,20:11:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,15:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,20:09:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital
VRTX,2024-05-31,15:00:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,20:21:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:10:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:14:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic -2-
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the -2-
VRTX,2024-06-07,20:09:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital
VRTX,2024-06-12,14:00:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-12,14:00:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:12:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo
VRTX,2024-06-26,14:27:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic
VRTX,2024-06-27,20:06:49,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-06-28,20:05:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance Of New Drug Application For Vanzacaftor,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Acceptance Of New Drug Application For Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment For Cystic Fibrosis >VRTX"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-10,14:33:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley
VRTX,2024-07-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA >VRTX
VRTX,2024-07-15,20:50:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-15,21:05:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-16,13:15:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: the company's collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX,PRESS-RELEASE,PR Newswire,Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald
VRTX,2024-07-22,17:18:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen
VRTX,2024-07-24,16:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-24,20:07:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-25,20:07:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Business Wire,Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:11:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: FDA Grants Priority Review and Assigns a PDUFA Target Action Date of Jan. 30
VRTX,2024-07-30,17:27:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,17:42:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,19:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity
VRTX,2024-08-01,19:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss/Shr $13.92,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss/Shr $13.92 >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss $3.59B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss $3.59B >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -5-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -5-
VRTX,2024-08-01,20:02:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX
VRTX,2024-08-01,20:02:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX
VRTX,2024-08-01,20:10:41,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook -- IBD
VRTX,2024-08-01,20:18:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim
VRTX,2024-08-02,20:13:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
VRTX,2024-08-05,14:29:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.
VRTX,2024-08-07,13:54:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,15:51:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-12,20:09:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-19,07:00:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)"
VRTX,2024-08-21,07:12:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Alpine Immune Sciences Inc, Inst Holders, 2Q 2024 (ALPN)",RNS-SEC13F,Dow Jones Newswires,"Alpine Immune Sciences  Inc, Inst Holders, 2Q 2024 (ALPN)"
VRTX,2024-08-30,20:27:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-30,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:20:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-09-25,20:22:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-25,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of -3-
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral -3-
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley
VRTX,2024-10-02,14:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-03,20:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 999 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.32,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS
VRTX,2024-10-18,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Business Wire,"Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-18,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney -2-
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on -2-
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.38,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.05B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.05B >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -5-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -5-
VRTX,2024-11-04,21:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Beats Third-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Beats Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex expects to launch a next-generation treatment,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,earnings,above-expectations,Vertex Pharmaceuticals beat Wall Street's third-quarter expectations,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,"During the third quarter, Vertex's sales climbed 12% to $2.77 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
VRTX,2024-11-08,20:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,14:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,21:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-13,21:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Citigroup
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup
VRTX,2024-11-15,15:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-11-19,08:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)"
VRTX,2024-11-19,21:11:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 15 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Business Wire,Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-08,17:52:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies
VRTX,2024-12-10,12:21:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,products-services,negative,Cervomed Phase 2b Study of Neflamapimod Misses,FULL-ARTICLE,Dow Jones Newswires,CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results From Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of -2-
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint >VRTX
VRTX,2024-12-19,15:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,GlobeNewswire,Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.
VRTX,2024-12-20,13:00:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals to report adjusted earnings of $4.05 per share,FULL-ARTICLE,Dow Jones Newswires,Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? -- IBD
VRTX,2024-12-20,13:45:25,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays
VRTX,2024-12-20,20:35:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) To Include Additional Non-F508del TRIKAFTA-Responsive Variants >VRTX
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA -2-
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,21:00:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:09:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,21:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:24:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,23:16:36,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock -- IBD
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities
VRTX,2024-12-23,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Business Wire,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-12-23,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-01-02,15:36:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-04,21:21:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-07,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex Pharmaceuticals Inc.: UK) for Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: VX-880: Completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-264: The clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,10:38:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex also submitted an Investigational New Drug (IND) application to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2024-01-08,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-10,21:07:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces US FDA Approval Of CASGEVY(TM) (exagamglogene Autotemcel) For The Treatment Of Transfusion-Dependent Beta Thalassemia >VRTX
VRTX,2024-01-16,19:24:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Business Wire,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:24:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
VRTX,2024-01-16,19:37:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-16,19:52:27,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-17,13:04:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
VRTX,2024-01-18,14:00:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?"
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sell From Hold by Canaccord Genuity
VRTX,2024-01-24,11:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $332.00 by Canaccord Genuity
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-01-24,16:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $440.00/Share From $415.00 by Cantor Fitzgerald
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:28:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From the VX-548 -2-
VRTX,2024-01-30,11:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to Submit a New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to Submit a New Drug Application to FDA by Mid-2024 >VRTX
VRTX,2024-01-30,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Plans to File for FDA Approval by Mid-2024 -- WSJ
VRTX,2024-01-30,11:30:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company is also testing the same medicine in,FULL-ARTICLE,Dow Jones Newswires,Vertex Unveils Strong Data on Opioid Alternative -- Barrons.com
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: VX-548 Phase 3 Results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex conducted an additional Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: The safety profile in this study was generally consistent with randomized, controlled Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit a New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,11:32:55,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results -2-
VRTX,2024-01-30,16:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex's Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst. VRTX Stock Slips, Bounces Back. -- IBD"
VRTX,2024-01-30,18:13:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-30,21:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex plans to ask the Food and Drug Administration to approve VX-548,FULL-ARTICLE,Dow Jones Newswires,"Vertex Rebounds -- But Its Alternative To Opioids Is 'Not A Game-Changer, ' Says Analyst -- IBD"
VRTX,2024-01-31,15:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Maxim Group
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2024-01-31,16:20:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $559.00/Share From $442.00 by Goldman Sachs
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-01-31,20:02:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $508.00/Share From $456.00 by Truist Securities
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-01,14:47:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $390.00 by JP Morgan
VRTX,2024-02-02,11:37:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Bernstein
VRTX,2024-02-05,14:31:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?"
VRTX,2024-02-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.88,products-services,positive,Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.71,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.71 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $4.20,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $4.20 >VRTX
VRTX,2024-02-05,21:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $968.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $968.8M >VRTX
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -2-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -3-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -4-
VRTX,2024-02-05,21:06:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2023 -5-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $9.87 billion, an 11% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the fourth quarter of 2023 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in 2023 increased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex recently signed an agreement with Synergie,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to submit an NDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in two global Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex shared positive Phase 2 results with VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex anticipates initiating a Phase 2 study with an oral formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.76 $ 3.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 968.8 $ 818.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,096.5 $ 978.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,730.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2024-02-05,21:06:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2024-02-05,21:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Full Yr 2024 Pdt Rev Guidance of $10.55B to $10.75B >VRTX
VRTX,2024-02-05,21:20:24,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.20 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,above-expectations,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex said the increase in revenue,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For 2024, Vertex forecast revenue between $10.55 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates"
VRTX,2024-02-05,22:00:04,57CAAB,Vertex Pharmaceuticals Inc.,96,0.62,products-services,positive,Vertex Pharmaceuticals unveiled promising Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat -- IBD
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-02-06,11:55:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $457.00/Share From $397.00 by HC Wainwright & Co.
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to In-Line From Outperform by Evercore ISI Group
VRTX,2024-02-06,13:44:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $438.00/Share From $436.00 by Evercore ISI Group
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2024-02-06,16:01:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $472.00/Share From $446.00 by Barclays
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-02-06,16:12:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $397.00 by RBC Capital
VRTX,2024-02-06,16:24:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-02-06,16:24:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $540.00/Share From $500.00 by Wells Fargo
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-02-06,19:34:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $438.00 by JP Morgan
VRTX,2024-02-12,14:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,16:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,17:45:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,18:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-12,18:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:10:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 10,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-12,21:28:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 2,656 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:47:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:50:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,374 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,21:55:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 913 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,21:58:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,738 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,738 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:04:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,100 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:18:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,255 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,222 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-13,22:34:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 314 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 314 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-13,22:51:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,607 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:07:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,393 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,21:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,356 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-14,22:15:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,145 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-15,11:36:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Wolfe Research
VRTX,2024-02-15,16:21:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,655 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-16,21:09:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 9,011 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-19,08:00:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2023 (VRTX)"
VRTX,2024-02-20,15:24:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,15:24:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,15:33:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:00:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-20,16:33:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-20,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-20,21:07:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2024-02-21,14:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,14:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:21:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,15:48:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,15:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,16:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:24:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,804 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:30:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 801 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,21:42:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,254 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,21:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-21,22:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 16,378 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:51:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,22:56:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 4,118 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-21,23:00:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 6,562 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KALYDECO(R) for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,12:10:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Kalydeco for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-02-23,21:12:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:14:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 3,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,201 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:28:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,191 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-23,21:32:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 360 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 360 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,15:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Atkinson III Registers 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,15:54:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,16:15:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-26,16:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-26,18:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,239 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:36:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,21:42:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,21:52:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Atkinson III Sells 883 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:05:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:09:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-02-27,22:47:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,22:59:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-02-27,23:08:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,309 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-03-21,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) >VRTX
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX,2024-03-21,12:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1 Study in,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1 Study in Healthy Volunteers This Month >VRTX
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Canadian News Wire,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The NDS is supported by results from the ongoing Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: Exa-cel is approved as CASGEVY(R) for certain indications in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:00:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Announces New Drug Submission for Exagamglogene Autotemcel,NEWS-FLASH,Dow Jones Newswires,Vertex Announces New Drug Submission for Exagamglogene Autotemcel Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2024-04-01,15:01:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Gets Health Canada Priority Review of Exa-cel,NEWS-FLASH,Dow Jones Newswires,"Vertex Gets Health Canada Priority Review of Exa-cel in Sickle-Cell Diseas, Transfusion-Dependent Beta Thalassemia"
VRTX,2024-04-03,20:04:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 240 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 240 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2024 Financial Results on May 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-09,20:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2024 Financial Results on May 6
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement to Acquire Alpine,PRESS-RELEASE,Business Wire,Vertex Enters Into Agreement to Acquire Alpine -2-
VRTX,2024-04-10,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences,NEWS-FLASH,Dow Jones Newswires,Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Will Acquire Alpine for $65,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Will Acquire Alpine for $65 Per Shr or About $4.9 B in Cash >VRTX ALPN
VRTX,2024-04-10,20:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,interest,Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk,NEWS-FLASH,Dow Jones Newswires,Vertex Subsidiary of Vertex Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire Alpine for $65 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex will host a conference call and webcast at 4:30 pm ET today, April 10, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
VRTX,2024-04-10,20:15:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B
VRTX,2024-04-10,20:30:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,20:39:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:09:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:15:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
VRTX,2024-04-10,21:24:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:25:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:40:16,57CAAB,Vertex Pharmaceuticals Inc.,93,0.62,acquisitions-mergers,,Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-10,21:47:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:06:23,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Dow Jones Newswires,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs ---- By Ben Glickman and Jennifer Calfas
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine is,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported $9.87 billion in product revenue last year,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,06:32:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex plans to file for approval with the FDA,FULL-ARTICLE,Wall Street Journal,Deal for Alpine Increases Vertex's Portfolio of Kidney-Disease Drugs -- WSJ
VRTX,2024-04-11,08:50:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Thursday: Vertex Pharmaceuticals, Boeing, Constellation Brands -- WSJ"
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From In-Line by Evercore ISI Group
VRTX,2024-04-11,11:00:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $438.00/Share by Evercore ISI Group
VRTX,2024-04-11,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences,FULL-ARTICLE,Dow Jones Newswires,VC Health Pulse: Magenta Medical Advances New Heart-Pump Technology; Vertex Pharmaceuticals Agrees to Buy Alpine Immune Sciences
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-04-11,12:02:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $462.00/Share From $457.00 by HC Wainwright & Co.
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,12:06:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,MW Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex (VRTX) said late Wednesday it was acquiring Alpine (ALPN) for $65 a share,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,acquisitions-mergers,,Vertex Pharma's $4.9 billion takeover of Alpine Immune,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,14:50:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,William Blair has an outperform rating on Vertex,FULL-ARTICLE,MarketWatch,"MW Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says"
VRTX,2024-04-11,20:18:48,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He reiterated his buy rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD
VRTX,2024-04-12,16:12:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-04-15,12:03:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-04-18,11:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.66,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $466.00/Share From $498.00 by UBS
VRTX,2024-04-18,11:54:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-04-18,11:54:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $445.00 by Guggenheim
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Business Wire,Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex released positive results from its Phase 2 study in December 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:00:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex also anticipates initiating a Phase 1 study of an intravenous formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
VRTX,2024-04-18,12:59:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex is also set to launch Phase 3 trials,FULL-ARTICLE,MarketWatch,MW Vertex's stock climbs as non-opioid pain treatment advances
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Canadian News Wire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,(PR) VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,04:45:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Treefrog and Vertex to collaborate on,PRESS-RELEASE,PR Newswire,VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
VRTX,2024-04-23,13:44:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-23,13:59:04,57CAAB,Vertex Pharmaceuticals Inc.,95,0.39,products-services,,Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VRTX,2024-04-26,15:43:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Business Wire,Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for KALYDECO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Commission Approval for KALYDECO(R) to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-04-26,15:43:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces European Commission Approval for Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Announces European Commission Approval for Kalydeco to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
VRTX,2024-05-02,14:09:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-03,20:12:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 467 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -2-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -3-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -4-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2024 Financial -5-
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $4.21,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX
VRTX,2024-05-06,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX
VRTX,2024-05-06,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $1.1B >VRTX
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.69 billion, a 13% increase compared to Q1 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,"Vertex Pharmaceuticals Inc.: In the first quarter, Vertex shared positive results from the three Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: We also recently announced the acquisition of Alpine Immune Sciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the first quarter of 2024 increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission has granted approval for KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex has signed multiple agreements with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 Financial Results
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The FDA cleared the investigational new drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex has initiated a Phase 1 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Vertex will acquire Alpine for approximately $4.9 billion in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -2-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,241.8 $ 794.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.26 $ 2.72,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -3-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 23,917.4 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -4-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex's annual report on Form 10-K for the year ended December 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2024 -5-
VRTX,2024-05-06,20:03:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX
VRTX,2024-05-06,20:03:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: the company reported adjusted earnings of $4.76 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:15:55,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Factset expected Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD"
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals 1Q Sales Up 13%,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,revenues,up,Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-06,21:00:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex stock analysts projected $16.52 earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD"
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-05-07,11:27:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $450.00 by Piper Sandler
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-05-07,15:13:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $417.00 by RBC Capital
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,unchanged,Vertex reiterated its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,He has an outperform rating on Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,analyst-ratings,neutral,"Rbc analyst, on the other hand, has a sector perform rating on Vertex",FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-07,20:07:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Medicines Agency to approve vanzacaftor for cystic fibrosis,FULL-ARTICLE,Dow Jones Newswires,Vertex's Pain Drug Could Be Worth Up To $11.4 Billion -- Ongoing Debate Sparks Shares -- IBD
VRTX,2024-05-14,17:14:38,57CAAB,Vertex Pharmaceuticals Inc.,98,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock -- IBD
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals posted rising EPS,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-14,17:48:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex reported a 56% surge in earnings to $4.76,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Hit All-Time High, Paused, And Is Rising Again -- IBD"
VRTX,2024-05-15,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Business Wire,Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Schneider Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Jennifer Schneider Elected to Vertex Board of Directors
VRTX,2024-05-15,14:30:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Names Jennifer Schneider to Board,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Names Jennifer Schneider to Board >VRTX
VRTX,2024-05-15,15:45:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,15:54:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-15,16:24:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 54 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 54 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:26:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 69 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-17,20:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 32 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 32 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-05-19,07:00:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2024 (VRTX)"
VRTX,2024-05-20,12:36:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-05-20,19:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,17:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-22,20:23:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,17:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:14:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 7,073 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-24,20:28:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,unchanged,Vertex reiterated its 2024 outlook for sales,FULL-ARTICLE,Dow Jones Newswires,New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout -- IBD
VRTX,2024-05-28,15:30:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,14:09:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-29,20:11:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 1,565 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,15:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,350 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-30,20:09:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-05-31,13:52:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.5,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $480.00 by BMO Capital
VRTX,2024-05-31,15:00:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-05-31,20:21:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,17:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-03,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:10:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,175 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-05,20:14:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Presents New Data at the European Cystic -2-
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA(R)
VRTX,2024-06-07,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data at the -2-
VRTX,2024-06-07,20:09:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 4,600 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-06-11,11:46:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $421.00/Share From $424.00 by RBC Capital
VRTX,2024-06-12,14:00:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-12,14:00:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 7,288 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-13,20:12:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2024-06-17,17:15:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $465.00 by Argus Research
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The original 17-patient study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
VRTX,2024-06-21,19:45:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2024-06-24,13:12:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $555.00/Share From $540.00 by Wells Fargo
VRTX,2024-06-26,14:27:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
VRTX,2024-06-27,09:57:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $545.00/Share by Redburn Atlantic
VRTX,2024-06-27,20:06:49,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Incorporated (""Vertex"") completed its acquisition of Alpine Immune Sciences, Inc.",RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2024-06-28,20:05:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2024 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-01,20:20:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance Of New Drug Application For Vanzacaftor,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Acceptance Of New Drug Application For Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment For Cystic Fibrosis >VRTX"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: EU Marketing Authorization Application (MAA) submission,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-02,12:33:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Fda Acceptance of New Drug Application for Vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis"
VRTX,2024-07-10,14:33:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-07-11,17:20:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $455.00/Share From $402.00 by Morgan Stanley
VRTX,2024-07-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
VRTX,2024-07-15,13:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Marketing Authorization for Expanded Use of TRIKAFTA >VRTX
VRTX,2024-07-15,20:50:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-15,21:05:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,legal,,Vertex Sues U.S. to,FULL-ARTICLE,Dow Jones Newswires,Vertex Sues U.S. to Pay for Fertility Treatments
VRTX,2024-07-16,13:15:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: the company's collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX,PRESS-RELEASE,PR Newswire,Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-07-19,11:12:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2024-07-22,15:46:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $480.00/Share From $440.00 by Cantor Fitzgerald
VRTX,2024-07-22,17:18:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by TD Cowen
VRTX,2024-07-23,17:20:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $450.00 by TD Cowen
VRTX,2024-07-24,16:30:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-24,20:07:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-25,20:07:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Business Wire,Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:10:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
VRTX,2024-07-30,17:11:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: FDA Grants Priority Review and Assigns a PDUFA Target Action Date of Jan. 30
VRTX,2024-07-30,17:27:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,17:42:34,57CAAB,Vertex Pharmaceuticals Inc.,92,0.0,products-services,,Vertex Pharmaceuticals said the U.S. Food and Drug Administration has accepted its new drug application,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
VRTX,2024-07-30,19:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-07-31,12:48:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $376.00/Share From $371.00 by Canaccord Genuity
VRTX,2024-08-01,19:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss/Shr $13.92,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss/Shr $13.92 >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals 2Q Loss $3.59B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Loss $3.59B >VRTX
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2024 Financial -5-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.65 billion, a 6% increase compared to Q2 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are increasing our full year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2024 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D expenses were $4.4 billion compared to $111 million in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission granted approval to KALYDECO for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 Financial Results
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in its Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex announced positive results from the ongoing Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -2-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -3-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,132.1 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -4-
VRTX,2024-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2024 -5-
VRTX,2024-08-01,20:02:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX
VRTX,2024-08-01,20:02:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX
VRTX,2024-08-01,20:10:41,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook -- IBD
VRTX,2024-08-01,20:18:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,202 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,"For the full year, Vertex now expects total product revenue between $10.65 billion",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-01,20:45:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,"On an adjusted basis, Vertex reported a loss of $12.83",FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments"
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2024-08-02,14:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $535.00/Share From $500.00 by Piper Sandler
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2024-08-02,19:43:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $558.00/Share From $450.00 by Guggenheim
VRTX,2024-08-02,20:13:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 5,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Barclays
VRTX,2024-08-05,10:59:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
VRTX,2024-08-05,14:29:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $508.00 by Truist Securities
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-08-05,15:06:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $510.00/Share From $505.00 by JP Morgan
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-08-05,16:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Oppenheimer
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-08-05,19:39:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.
VRTX,2024-08-07,13:54:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,15:51:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Bhatia Registers 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-08,20:09:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 2,280 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-12,20:09:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,292 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-19,07:00:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2024 (VRTX)"
VRTX,2024-08-21,07:12:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Alpine Immune Sciences Inc, Inst Holders, 2Q 2024 (ALPN)",RNS-SEC13F,Dow Jones Newswires,"Alpine Immune Sciences  Inc, Inst Holders, 2Q 2024 (ALPN)"
VRTX,2024-08-30,20:27:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-08-30,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 646 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-09-04,20:20:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 3,784 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-09-25,20:22:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-25,20:37:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Vertex Highlights First Oral Presentation of -3-
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2024-09-26,11:07:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This is the first time that the clinical data from the Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Highlights First Oral -3-
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-10-01,11:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $474.00/Share From $462.00 by Morgan Stanley
VRTX,2024-10-02,14:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-03,20:14:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 999 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 999 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-04,15:36:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $425.00/Share From $431.00 by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-10-09,15:36:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $437.00/Share From $425.00 by RBC Capital
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2024 Financial Results on November 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-10,21:47:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2024 Financial Results on November 4th
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-10-14,17:58:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.32,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $541.00/Share From $550.00 by B of A Securities
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Sector Perform by Scotiabank
VRTX,2024-10-16,15:00:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $480.00/Share by Scotiabank
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-10-17,16:04:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $562.00/Share From $477.00 by UBS
VRTX,2024-10-18,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Business Wire,"Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-18,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"Vertex Pharmaceuticals Inc.: Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting"
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Provides Updates on Multiple Kidney -2-
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has now initiated RAINIER, a global Phase 3 clinical trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
VRTX,2024-10-25,17:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on -2-
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2024-10-30,16:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $540.00/Share From $550.00 by Oppenheimer
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.38,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.05B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.05B >VRTX
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2024 Financial -5-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.77 billion, a 12% increase compared to Q3 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Raising full-year product revenue guidance to $10.8 billion to $10.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again increasing our full-year product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2024 increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.58,equity-actions,down,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $15 million compared to $52 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: In the third quarter of 2024, Vertex's product revenue",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"July, Health Canada granted approval to TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,"Vertex Pharmaceuticals Inc.: VX-522, nebulized mRNA therapy",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 Financial Results
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated the RAINIER study, the Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in two global Phase 3 studies of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,"Mhra), Vertex has reached agreement to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -2-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -3-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,240.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -4-
VRTX,2024-11-04,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2024 -5-
VRTX,2024-11-04,21:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Beats Third-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals to earn $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:25:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Raises Full-Year Outlook After,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,21:44:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals again raised its full-year outlook after,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Beats Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex expects to launch a next-generation treatment,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-04,22:21:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD"
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2024-11-05,13:34:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $476.00/Share From $473.00 by Morgan Stanley
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,earnings,above-expectations,Vertex Pharmaceuticals beat Wall Street's third-quarter expectations,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,"During the third quarter, Vertex's sales climbed 12% to $2.77 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,15:06:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug -- IBD
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-11-05,16:34:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $510.00 by JP Morgan
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2024-11-05,17:00:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $451.00/Share From $437.00 by RBC Capital
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2024-11-05,18:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $586.00/Share From $562.00 by UBS
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-11-06,00:00:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
VRTX,2024-11-06,18:08:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
VRTX,2024-11-08,20:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,14:49:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-12,21:12:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 15,198 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-13,21:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Buy by Citigroup
VRTX,2024-11-14,13:03:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $575.00/Share by Citigroup
VRTX,2024-11-15,15:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-11-19,08:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2024 (VRTX)"
VRTX,2024-11-19,21:11:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 15 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 15 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2024-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Business Wire,Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-08,17:52:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY(TM) (exagamglogene autotemcel) from global clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
VRTX,2024-12-09,11:34:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $500.00 by Jefferies
VRTX,2024-12-10,12:21:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,products-services,negative,Cervomed Phase 2b Study of Neflamapimod Misses,FULL-ARTICLE,Dow Jones Newswires,CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2024-12-16,13:27:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $494.00/Share From $490.00 by Stifel
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results From Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results From Phase 2 Study of -2-
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,earnings,,Vertex Pharmaceuticals Inc.: Today's LSR results are consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The agency granted priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
VRTX,2024-12-19,11:00:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Vertex: Phase 2 Study of Suzetrigine in Painful Lumbosacral Radiculopathy Met Primary Endpoint >VRTX
VRTX,2024-12-19,15:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,GlobeNewswire,Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2024-12-19,17:34:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $522.00/Share From $545.00 by B of A Securities
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2024-12-20,12:08:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.
VRTX,2024-12-20,13:00:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals to report adjusted earnings of $4.05 per share,FULL-ARTICLE,Dow Jones Newswires,Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? -- IBD
VRTX,2024-12-20,13:45:25,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.8,products-services,negative,Vertex Pharmaceuticals Inc.: the company reported disappointing results from its RewinD-LB Phase 2b clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2024-12-20,16:47:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $520.00/Share From $566.00 by BMO Capital
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2024-12-20,18:25:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $418.00/Share From $509.00 by Barclays
VRTX,2024-12-20,20:35:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) To Include Additional Non-F508del TRIKAFTA-Responsive Variants >VRTX
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA -2-
VRTX,2024-12-20,20:35:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:00,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Business Wire,"Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: In Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces US FDA Approval of ALYFTREK(TM), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2024-12-20,21:00:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:09:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,21:15:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
VRTX,2024-12-20,21:24:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gains FDA Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
VRTX,2024-12-20,23:16:36,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock -- IBD
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2024-12-23,14:08:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $500.00/Share From $503.00 by JP Morgan
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2024-12-23,15:21:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2024-12-23,15:38:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $550.00 by Truist Securities
VRTX,2024-12-23,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Business Wire,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2024-12-23,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
VRTX,2021-01-07,14:01:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-07,14:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley
VRTX,2021-01-20,09:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)"
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-26,13:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations >VRTX
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:35:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: FDA Grants Priority Review of Application and Sets PDUFA Target Action Date of June 8, 2021 >VRTX"
VRTX,2021-01-26,13:55:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range >VRTX
VRTX,2021-01-26,14:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug (IND) Application For VX-880, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes (T1D) >VRTX"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $2.30,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $2.30 >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $604.2M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $604.2M >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -5-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,NEWS-FLASH,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -5-
VRTX,2021-02-01,21:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2020 Product Rev $6.2B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals 2020 Product Rev $6.2B, Sees 2021 Product Rev $6.7B-$6.9B>VRTX"
VRTX,2021-02-01,21:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $2.51,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $2.51 >VRTX
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-02,00:28:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript >VRTX
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler
VRTX,2021-02-05,21:45:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:54:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Parini Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Parini Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-05,21:56:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-10,00:45:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 1,930 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 1,930 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:04:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:10:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:15:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:19:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:21:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:22:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-12,21:28:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:30:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:06:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:29:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 4,318 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 4,318 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:31:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:33:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,498 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:07:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:19:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:21:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:23:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:26:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:29:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:38:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-23,11:08:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird
VRTX,2021-02-23,11:08:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird
VRTX,2021-02-24,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Business Wire,Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-24,14:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-26,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:22:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:28:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,080 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:31:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-26,21:32:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-03-02,21:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 2,782 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 2,782 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-05,11:59:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received four approvals for cystic fibrosis drugs,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Fell After a Setback on a New Drug. It's an Opportunity for Investors. -- Barrons.com
VRTX,2021-03-08,21:12:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 5,141 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 5,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-10,13:22:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes >VRTX
VRTX,2021-03-10,13:37:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes
VRTX,2021-03-10,18:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to begin Phase 1/2 trial of treatment,FULL-ARTICLE,MarketWatch,MW Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes
VRTX,2021-03-10,18:04:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex To Begin Phase 1/2 Trial Of Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex To Begin Phase 1/2 Trial Of Treatment For People With Type 1 Diabetes -- MarketWatch
VRTX,2021-03-24,23:21:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Receives Australian TGA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have at Least One F508del Mutation
VRTX,2021-03-26,11:23:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:23:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:28:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor to Treat People With Cystic Fibrosis With at Least One F508del Mutation
VRTX,2021-03-26,12:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-03-26,12:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-04-05,20:03:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-07,15:24:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex downgraded to underweight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex downgraded to underweight at Morgan Stanley
VRTX,2021-04-07,20:05:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley
VRTX,2021-04-20,11:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,GlobeNewswire,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,17:19:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-20,17:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $653.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $653.1M >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -4-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -4-
VRTX,2021-04-29,20:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-30,04:28:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-05-06,01:25:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 960 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 960 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-06,01:27:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-10,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-10,13:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-12,15:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
VRTX,2021-05-19,20:03:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 79 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 79 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:08:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:11:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-02,20:08:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-04,20:05:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:38:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,12:53:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,15:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:59:38,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,products-services,,Vertex says it will stop developing its experimental drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Suffers Latest Drug Pipeline Setback -- Market Talk
VRTX,2021-06-11,07:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2021-06-11,10:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.7,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital
VRTX,2021-06-11,11:26:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Stifel
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company disclosed results of a Phase 2 drug trial,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the company receiving approval for its drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Baird
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird
VRTX,2021-06-11,12:55:57,57CAAB,Vertex Pharmaceuticals Inc.,92,-0.52,products-services,,Vertex Pharmaceuticals Inc.: the company halted development of a drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising -- Barrons.com"
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler
VRTX,2021-06-24,11:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals to Repurchase Up to $1.5B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals to Repurchase Up to $1.5B of Its Common Stock through Dec. 31, 2022"
VRTX,2021-07-01,09:09:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2021-07-01,12:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals initiated at market perform at Raymond James,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals initiated at market perform at Raymond James
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-19,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Business Wire,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-20,08:36:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)"
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Business Wire,Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS 26c,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS 26c >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $66.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $66.9M >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -4-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 66,924 $ 837,270 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -4-
VRTX,2021-07-29,20:05:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Rev to $7.2 Bto $7.4B >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.3,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley
VRTX,2021-08-03,20:13:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Inc.: Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:38:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,12:53:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,20:07:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-23,12:32:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Arbor Biotechnologies Establish New Partnership to,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex will receive rights to use Arbor's technology,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley
VRTX,2021-09-07,14:44:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley
VRTX,2021-09-09,10:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel
VRTX,2021-09-13,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference on September 15(th)
VRTX,2021-09-13,12:14:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
VRTX,2021-09-17,20:19:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Canadian News Wire,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:21:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA
VRTX,2021-09-22,15:16:52,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-09-22,15:16:53,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,14:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration >MTEM
VRTX,2021-10-18,14:27:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-20,08:30:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)"
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-26,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:00:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Mammoth Biosciences Announce Collaboration to Develop in Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:06:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-27,16:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-10-27,16:07:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.28,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.28 >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $851.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $851.9M >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -4-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -4-
VRTX,2021-11-02,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Revenue to $7.4 Billion to $7.5 Billion >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q3-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Inc.: the company beat third-quarter earnings expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: The company reported product revenue of $2 billion, up 29%",FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex increased its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,20:15:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-12,12:27:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-12,12:27:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-16,21:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-16,21:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 51 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 51 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital
VRTX,2021-11-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,13:53:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 -2-
VRTX,2021-12-01,12:30:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:31:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo
VRTX,2021-01-07,14:01:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-07,14:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley
VRTX,2021-01-20,09:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)"
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-26,13:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations >VRTX
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:35:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: FDA Grants Priority Review of Application and Sets PDUFA Target Action Date of June 8, 2021 >VRTX"
VRTX,2021-01-26,13:55:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range >VRTX
VRTX,2021-01-26,14:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug (IND) Application For VX-880, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes (T1D) >VRTX"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $2.30,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $2.30 >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $604.2M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $604.2M >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -5-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,NEWS-FLASH,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -5-
VRTX,2021-02-01,21:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2020 Product Rev $6.2B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals 2020 Product Rev $6.2B, Sees 2021 Product Rev $6.7B-$6.9B>VRTX"
VRTX,2021-02-01,21:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $2.51,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $2.51 >VRTX
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-02,00:28:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript >VRTX
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler
VRTX,2021-02-05,21:45:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:54:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Parini Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Parini Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-05,21:56:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-10,00:45:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 1,930 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 1,930 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:04:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:10:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:15:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:19:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:21:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:22:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-12,21:28:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:30:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:06:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:29:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 4,318 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 4,318 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:31:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:33:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,498 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:07:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:19:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:21:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:23:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:26:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:29:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:38:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-23,11:08:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird
VRTX,2021-02-23,11:08:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird
VRTX,2021-02-24,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Business Wire,Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-24,14:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-26,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:22:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:28:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,080 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:31:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-26,21:32:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-03-02,21:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 2,782 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 2,782 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-05,11:59:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received four approvals for cystic fibrosis drugs,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Fell After a Setback on a New Drug. It's an Opportunity for Investors. -- Barrons.com
VRTX,2021-03-08,21:12:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 5,141 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 5,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-10,13:22:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes >VRTX
VRTX,2021-03-10,13:37:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes
VRTX,2021-03-10,18:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to begin Phase 1/2 trial of treatment,FULL-ARTICLE,MarketWatch,MW Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes
VRTX,2021-03-10,18:04:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex To Begin Phase 1/2 Trial Of Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex To Begin Phase 1/2 Trial Of Treatment For People With Type 1 Diabetes -- MarketWatch
VRTX,2021-03-24,23:21:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Receives Australian TGA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have at Least One F508del Mutation
VRTX,2021-03-26,11:23:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:23:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:28:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor to Treat People With Cystic Fibrosis With at Least One F508del Mutation
VRTX,2021-03-26,12:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-03-26,12:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-04-05,20:03:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-07,15:24:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex downgraded to underweight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex downgraded to underweight at Morgan Stanley
VRTX,2021-04-07,20:05:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley
VRTX,2021-04-20,11:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,GlobeNewswire,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,17:19:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-20,17:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $653.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $653.1M >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -4-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -4-
VRTX,2021-04-29,20:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-30,04:28:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-05-06,01:25:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 960 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 960 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-06,01:27:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-10,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-10,13:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-12,15:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
VRTX,2021-05-19,20:03:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 79 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 79 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:08:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:11:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-02,20:08:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-04,20:05:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:38:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,12:53:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,15:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:59:38,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,products-services,,Vertex says it will stop developing its experimental drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Suffers Latest Drug Pipeline Setback -- Market Talk
VRTX,2021-06-11,07:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2021-06-11,10:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.7,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital
VRTX,2021-06-11,11:26:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Stifel
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company disclosed results of a Phase 2 drug trial,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the company receiving approval for its drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Baird
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird
VRTX,2021-06-11,12:55:57,57CAAB,Vertex Pharmaceuticals Inc.,92,-0.52,products-services,,Vertex Pharmaceuticals Inc.: the company halted development of a drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising -- Barrons.com"
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler
VRTX,2021-06-24,11:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals to Repurchase Up to $1.5B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals to Repurchase Up to $1.5B of Its Common Stock through Dec. 31, 2022"
VRTX,2021-07-01,09:09:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2021-07-01,12:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals initiated at market perform at Raymond James,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals initiated at market perform at Raymond James
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-19,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Business Wire,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-20,08:36:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)"
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Business Wire,Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS 26c,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS 26c >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $66.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $66.9M >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -4-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 66,924 $ 837,270 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -4-
VRTX,2021-07-29,20:05:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Rev to $7.2 Bto $7.4B >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.3,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley
VRTX,2021-08-03,20:13:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Inc.: Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:38:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,12:53:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,20:07:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-23,12:32:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Arbor Biotechnologies Establish New Partnership to,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex will receive rights to use Arbor's technology,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley
VRTX,2021-09-07,14:44:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley
VRTX,2021-09-09,10:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel
VRTX,2021-09-13,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference on September 15(th)
VRTX,2021-09-13,12:14:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
VRTX,2021-09-17,20:19:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Canadian News Wire,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:21:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA
VRTX,2021-09-22,15:16:52,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-09-22,15:16:53,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,14:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration >MTEM
VRTX,2021-10-18,14:27:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-20,08:30:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)"
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-26,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:00:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Mammoth Biosciences Announce Collaboration to Develop in Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:06:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-27,16:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-10-27,16:07:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.28,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.28 >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $851.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $851.9M >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -4-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -4-
VRTX,2021-11-02,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Revenue to $7.4 Billion to $7.5 Billion >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q3-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Inc.: the company beat third-quarter earnings expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: The company reported product revenue of $2 billion, up 29%",FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex increased its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,20:15:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-12,12:27:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-12,12:27:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-16,21:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-16,21:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 51 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 51 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital
VRTX,2021-11-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,13:53:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 -2-
VRTX,2021-12-01,12:30:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:31:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo
VRTX,2021-01-07,14:01:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-07,14:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley
VRTX,2021-01-20,09:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)"
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-26,13:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations >VRTX
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:35:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: FDA Grants Priority Review of Application and Sets PDUFA Target Action Date of June 8, 2021 >VRTX"
VRTX,2021-01-26,13:55:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range >VRTX
VRTX,2021-01-26,14:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug (IND) Application For VX-880, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes (T1D) >VRTX"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $2.30,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $2.30 >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $604.2M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $604.2M >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -5-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,NEWS-FLASH,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -5-
VRTX,2021-02-01,21:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2020 Product Rev $6.2B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals 2020 Product Rev $6.2B, Sees 2021 Product Rev $6.7B-$6.9B>VRTX"
VRTX,2021-02-01,21:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $2.51,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $2.51 >VRTX
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-02,00:28:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript >VRTX
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler
VRTX,2021-02-05,21:45:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:54:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Parini Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Parini Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-05,21:56:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-10,00:45:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 1,930 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 1,930 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:04:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:10:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:15:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:19:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:21:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:22:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-12,21:28:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:30:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:06:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:29:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 4,318 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 4,318 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:31:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:33:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,498 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:07:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:19:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:21:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:23:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:26:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:29:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:38:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-23,11:08:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird
VRTX,2021-02-23,11:08:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird
VRTX,2021-02-24,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Business Wire,Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-24,14:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-26,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:22:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:28:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,080 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:31:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-26,21:32:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-03-02,21:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 2,782 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 2,782 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-05,11:59:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received four approvals for cystic fibrosis drugs,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Fell After a Setback on a New Drug. It's an Opportunity for Investors. -- Barrons.com
VRTX,2021-03-08,21:12:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 5,141 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 5,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-10,13:22:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes >VRTX
VRTX,2021-03-10,13:37:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes
VRTX,2021-03-10,18:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to begin Phase 1/2 trial of treatment,FULL-ARTICLE,MarketWatch,MW Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes
VRTX,2021-03-10,18:04:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex To Begin Phase 1/2 Trial Of Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex To Begin Phase 1/2 Trial Of Treatment For People With Type 1 Diabetes -- MarketWatch
VRTX,2021-03-24,23:21:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Receives Australian TGA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have at Least One F508del Mutation
VRTX,2021-03-26,11:23:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:23:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:28:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor to Treat People With Cystic Fibrosis With at Least One F508del Mutation
VRTX,2021-03-26,12:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-03-26,12:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-04-05,20:03:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-07,15:24:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex downgraded to underweight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex downgraded to underweight at Morgan Stanley
VRTX,2021-04-07,20:05:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley
VRTX,2021-04-20,11:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,GlobeNewswire,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,17:19:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-20,17:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $653.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $653.1M >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -4-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -4-
VRTX,2021-04-29,20:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-30,04:28:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-05-06,01:25:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 960 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 960 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-06,01:27:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-10,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-10,13:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-12,15:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
VRTX,2021-05-19,20:03:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 79 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 79 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:08:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:11:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-02,20:08:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-04,20:05:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:38:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,12:53:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,15:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:59:38,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,products-services,,Vertex says it will stop developing its experimental drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Suffers Latest Drug Pipeline Setback -- Market Talk
VRTX,2021-06-11,07:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2021-06-11,10:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.7,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital
VRTX,2021-06-11,11:26:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Stifel
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company disclosed results of a Phase 2 drug trial,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the company receiving approval for its drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Baird
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird
VRTX,2021-06-11,12:55:57,57CAAB,Vertex Pharmaceuticals Inc.,92,-0.52,products-services,,Vertex Pharmaceuticals Inc.: the company halted development of a drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising -- Barrons.com"
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler
VRTX,2021-06-24,11:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals to Repurchase Up to $1.5B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals to Repurchase Up to $1.5B of Its Common Stock through Dec. 31, 2022"
VRTX,2021-07-01,09:09:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2021-07-01,12:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals initiated at market perform at Raymond James,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals initiated at market perform at Raymond James
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-19,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Business Wire,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-20,08:36:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)"
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Business Wire,Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS 26c,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS 26c >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $66.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $66.9M >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -4-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 66,924 $ 837,270 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -4-
VRTX,2021-07-29,20:05:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Rev to $7.2 Bto $7.4B >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.3,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley
VRTX,2021-08-03,20:13:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Inc.: Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:38:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,12:53:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,20:07:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-23,12:32:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Arbor Biotechnologies Establish New Partnership to,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex will receive rights to use Arbor's technology,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley
VRTX,2021-09-07,14:44:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley
VRTX,2021-09-09,10:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel
VRTX,2021-09-13,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference on September 15(th)
VRTX,2021-09-13,12:14:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
VRTX,2021-09-17,20:19:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Canadian News Wire,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:21:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA
VRTX,2021-09-22,15:16:52,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-09-22,15:16:53,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,14:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration >MTEM
VRTX,2021-10-18,14:27:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-20,08:30:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)"
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-26,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:00:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Mammoth Biosciences Announce Collaboration to Develop in Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:06:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-27,16:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-10-27,16:07:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.28,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.28 >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $851.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $851.9M >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -4-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -4-
VRTX,2021-11-02,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Revenue to $7.4 Billion to $7.5 Billion >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q3-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Inc.: the company beat third-quarter earnings expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: The company reported product revenue of $2 billion, up 29%",FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex increased its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,20:15:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-12,12:27:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-12,12:27:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-16,21:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-16,21:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 51 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 51 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital
VRTX,2021-11-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,13:53:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 -2-
VRTX,2021-12-01,12:30:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:31:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo
VRTX,2021-01-07,14:01:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-07,14:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-01-19,15:18:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $251.00/Share From $249.00 by Morgan Stanley
VRTX,2021-01-20,09:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2020 (VRTX)"
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-22,14:01:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
VRTX,2021-01-26,13:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application,NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations >VRTX
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:30:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-01-26,13:35:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals: FDA Grants Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: FDA Grants Priority Review of Application and Sets PDUFA Target Action Date of June 8, 2021 >VRTX"
VRTX,2021-01-26,13:55:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range >VRTX
VRTX,2021-01-26,14:10:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Priority Review of Expanded Trikafta Age Range
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug (IND) Application For VX-880, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes (T1D) >VRTX"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-01-28,21:11:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex will initiate a Phase 1/2 clinical trial in first half of 2021,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)"
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $2.30,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $2.30 >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $604.2M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $604.2M >VRTX
VRTX,2021-02-01,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $1.63B >VRTX
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Business Wire,Vertex Reports Full-Year and Fourth-Quarter 2020 -5-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Full-year 2020 GAAP product revenues of $6.20 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.30 $ 2.23,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,revenues,up,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP product revenues increased 49% and 55%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The U.S. FDA accepted a supplemental New Drug Application (sNDA) for TRIKAFTA for the treatment of children with CF,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex expects to initiate a Phase 1/2 clinical trial in the first half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Skyhawk Therapeutics and Vertex established a strategic collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 604,190 $ 583,234",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -2-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.32 $ 2.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,627,820 $1,413,265",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,626,920 $1,257,492",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 203,101 $ 185,012 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 11,751,808 $ 8,318,465",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -3-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -4-
VRTX,2021-02-01,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Full-Year,NEWS-FLASH,Dow Jones Newswires,Press Release: Vertex Reports Full-Year and -5-
VRTX,2021-02-01,21:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2020 Product Rev $6.2B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals 2020 Product Rev $6.2B, Sees 2021 Product Rev $6.7B-$6.9B>VRTX"
VRTX,2021-02-01,21:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $2.51,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $2.51 >VRTX
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:14:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals' 4Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-01,21:29:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc. reported higher profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals' 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review"
VRTX,2021-02-02,00:28:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q4 2020 Results -- Earnings Call Transcript >VRTX
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-02-02,11:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $250.00/Share From $257.00 by SVB Leerink
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Credit Suisse
VRTX,2021-02-02,14:01:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $280.00/Share From $285.00 by Credit Suisse
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2021-02-02,17:01:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $284.00/Share From $302.00 by BMO Capital
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-02-02,17:19:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $347.00/Share From $307.00 by Piper Sandler
VRTX,2021-02-05,21:45:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:54:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Parini Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Parini Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-05,21:56:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 12,329 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-05,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 3,391 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-10,00:45:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 1,930 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 1,930 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:14:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,954 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:04:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,974 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Surrenders 3,101 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,367 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:10:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:15:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Surrenders 2,563 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:19:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,421 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:21:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:22:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Silva Surrenders 651 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-12,21:28:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,230 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-12,21:30:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,365 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:06:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 5,283 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 5,156 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:29:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 4,318 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 4,318 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:31:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:33:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,498 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-16,21:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 4,460 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:07:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:19:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:21:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 7,825 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 7,825 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:23:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 9,264 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:26:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 4,295 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 4,295 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:29:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-19,21:38:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-23,11:08:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird
VRTX,2021-02-23,11:08:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird
VRTX,2021-02-24,14:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Business Wire,Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-24,14:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Cowen Health Care Conference on March 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Cowen Health Care Conference on March 2
VRTX,2021-02-26,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Arbuckle Sells 3,634 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:22:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Parini Sells 3,028 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Parini Sells 3,028 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:25:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,586 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:28:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 1,080 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 1,080 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:31:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-02-26,21:32:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 2,898 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Surrenders 1,036 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-02-26,21:47:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-03-02,21:10:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Silva Sells 2,782 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Silva Sells 2,782 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-05,11:59:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received four approvals for cystic fibrosis drugs,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Fell After a Setback on a New Drug. It's an Opportunity for Investors. -- Barrons.com
VRTX,2021-03-08,21:12:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 5,141 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 5,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-03-10,13:22:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes >VRTX
VRTX,2021-03-10,13:37:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.69,products-services,,Vertex Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets FDA Fast-Track Designation for VX-880 in Type 1 Diabetes
VRTX,2021-03-10,18:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to begin Phase 1/2 trial of treatment,FULL-ARTICLE,MarketWatch,MW Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes
VRTX,2021-03-10,18:04:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex To Begin Phase 1/2 Trial Of Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex To Begin Phase 1/2 Trial Of Treatment For People With Type 1 Diabetes -- MarketWatch
VRTX,2021-03-24,23:21:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives Australian TGA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
VRTX,2021-03-24,23:21:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Receives Australian TGA Approval for TRIKAFTA,NEWS-FLASH,Dow Jones Newswires,Vertex Receives Australian TGA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have at Least One F508del Mutation
VRTX,2021-03-26,11:23:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:23:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The CHMP positive opinion was based on the results from a global Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
VRTX,2021-03-26,11:28:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor to Treat People With Cystic Fibrosis With at Least One F508del Mutation
VRTX,2021-03-26,12:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-03-26,12:20:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets CHMP Positive Opinion for Kaftrio With Ivacaftor
VRTX,2021-04-05,20:03:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-07,15:24:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex downgraded to underweight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex downgraded to underweight at Morgan Stanley
VRTX,2021-04-07,20:05:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,686 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First-Quarter 2021 Financial Results on April 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,13:04:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First-Quarter 2021 Financial Results on April 29
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-04-19,15:34:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $251.00 by Morgan Stanley
VRTX,2021-04-20,11:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,GlobeNewswire,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,11:15:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia"
VRTX,2021-04-20,17:19:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-20,17:34:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Collaboration Deal,FULL-ARTICLE,Dow Jones Newswires,CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Business Wire,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:00:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and Obsidian Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-22,12:08:44,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: The Company expects to submit an IND in mid-2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-26,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $653.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $653.1M >VRTX
VRTX,2021-04-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $1.72B >VRTX
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports First-Quarter 2021 Financial -4-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Net income $ 653 $ 603,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.72 billion, a 14% increase compared to Q1 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Multiple Phase 2 proof-of-concept study results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: our agreement with CRISPR Therapeutics for the CTX001 program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP Net income per share - diluted $ 2.49 $ 2.29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 14%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and CRISPR Therapeutics amended their collaboration for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Completion of enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 Financial Results
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 781,216 $ 674,454",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 2.32,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -2-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $ 1,724,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $ 1,723,305 $ 1,515,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 192,329 $ 162,497",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,115,059 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -3-
VRTX,2021-04-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First-Quarter 2021 -4-
VRTX,2021-04-29,20:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 3,884 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:12:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Posts Higher 1Q Profit,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-29,20:27:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex saw an increase in sales from Kaftrio in Europe,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Posts Higher 1Q Profit, Sales"
VRTX,2021-04-30,04:28:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-05-06,01:25:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 960 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 960 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-06,01:27:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-10,13:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-10,13:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
VRTX,2021-05-12,15:00:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,GlobeNewswire,Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
VRTX,2021-05-19,20:03:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 79 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 79 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Arbuckle Sells 109 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:08:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-05-19,20:11:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 112 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 112 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-02,20:08:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-04,20:05:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 559 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-09,12:38:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,12:53:47,57CAAB,Vertex Pharmaceuticals Inc.,93,0.53,products-services,complete,Vertex completed a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
VRTX,2021-06-09,15:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved expanded use of TRIKAFTA(R),PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:03:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,"Vertex will host an investor conference call and webcast today, Thursday, June 10 at 4:30 p.m. EDT",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:04:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
VRTX,2021-06-10,20:59:38,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,products-services,,Vertex says it will stop developing its experimental drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Suffers Latest Drug Pipeline Setback -- Market Talk
VRTX,2021-06-11,07:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2021-06-11,10:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $245 from $260 at Evercore ISI
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2021-06-11,10:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $302.00 by Barclays
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-06-11,11:12:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.7,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $242.00/Share From $262.00 by RBC Capital
VRTX,2021-06-11,11:26:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target cut to $244 from $277 at Stifel Nicolaus
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Stifel
VRTX,2021-06-11,12:30:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $244.00/Share From $277.00 by Stifel
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2021-06-11,12:36:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $281.00/Share From $285.00 by Cantor Fitzgerald
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company disclosed results of a Phase 2 drug trial,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:37:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the company receiving approval for its drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Shares Fall as Drug Fails. Analysts Say It's Time to Buy. -- Barrons.com
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Goldman Sachs
VRTX,2021-06-11,12:38:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $307.00/Share From $358.00 by Goldman Sachs
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Baird
VRTX,2021-06-11,12:52:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $240.00/Share From $252.00 by Baird
VRTX,2021-06-11,12:55:57,57CAAB,Vertex Pharmaceuticals Inc.,92,-0.52,products-services,,Vertex Pharmaceuticals Inc.: the company halted development of a drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising -- Barrons.com"
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2021-06-11,12:58:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $325.00 by Citigroup
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-06-11,13:05:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $205.00/Share From $254.00 by Morgan Stanley
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
VRTX,2021-06-14,10:45:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $200.00/Share From $250.00 by SVB Leerink
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2021-06-14,13:54:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $331.00/Share From $305.00 by Truist Securities
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-06-14,14:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $261.00/Share From $347.00 by Piper Sandler
VRTX,2021-06-24,11:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals to Repurchase Up to $1.5B,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals to Repurchase Up to $1.5B of Its Common Stock through Dec. 31, 2022"
VRTX,2021-07-01,09:09:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2021-07-01,12:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals initiated at market perform at Raymond James,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals initiated at market perform at Raymond James
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second-Quarter 2021 Financial Results on July 29,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-16,20:01:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second-Quarter 2021 Financial Results on July 29
VRTX,2021-07-19,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Business Wire,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-19,12:00:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2 Clinical Trial Program for,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
VRTX,2021-07-20,08:36:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2021 (VRTX)"
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underperform From Market Perform by SVB Leerink
VRTX,2021-07-20,11:29:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $170.00/Share From $200.00 by SVB Leerink
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Business Wire,Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-28,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS 26c,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS 26c >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $66.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $66.9M >VRTX
VRTX,2021-07-29,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $1.79B >VRTX
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Second-Quarter 2021 Financial -4-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 67 $ 837,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.79 billion, an 18% increase compared to Q2 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Pharmaceuticals Inc.: We have now secured reimbursement agreements for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: our 2021 revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 0.26 $ 3.18,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Product revenues increased 18%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full-Year 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.2 to 7.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted Marketing Authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 Financial Results
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex anticipates achieving target enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: A Phase 1/2 clinical trial for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 66,924 $ 837,270 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 0.26 $ 3.22 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -2-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 811,273 $ 686,804",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,-0.63,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,793,370 $1,524,485",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 227,972 $ 184,520 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,91,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,221,686 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -3-
VRTX,2021-07-29,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 5:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second-Quarter 2021 -4-
VRTX,2021-07-29,20:05:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Rev to $7.2 Bto $7.4B >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,03:13:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q2 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Underperform by SVB Leerink
VRTX,2021-07-30,11:23:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $175.00/Share From $170.00 by SVB Leerink
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-07-30,14:45:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $248.00/Share From $246.00 by RBC Capital
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2021-07-30,15:03:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $261.00 by Piper Sandler
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2021-07-30,16:44:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.3,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $202.00/Share From $205.00 by Morgan Stanley
VRTX,2021-08-03,20:13:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Stuart A. Arbuckle As Chief Operating Officer >VRTX
VRTX,2021-08-04,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Inc.: Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
VRTX,2021-08-04,12:38:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,12:53:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Names Stuart Arbuckle as Operating Chief,FULL-ARTICLE,Dow Jones Newswires,Vertex Names Stuart Arbuckle as Operating Chief
VRTX,2021-08-04,20:07:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 15,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-23,12:32:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Arbor Biotechnologies Establish New Partnership to,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-24,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex will receive rights to use Arbor's technology,PRESS-RELEASE,GlobeNewswire,Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:02:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharma Gets Approval for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-08-25,20:17:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada gave the biotechnology company marketing authorization for Ivacaftor,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma Gets Approval for Cystic Fibrosis Drug for Infants in Canada
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Underweight From Equal-Weight by Morgan Stanley
VRTX,2021-09-07,10:23:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by Morgan Stanley
VRTX,2021-09-07,14:44:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley
VRTX,2021-09-09,10:29:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Stifel
VRTX,2021-09-09,11:06:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $213.00/Share From $244.00 by Stifel
VRTX,2021-09-13,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Morgan Stanley Virtual 19(th) Annual Global Healthcare Conference on September 15(th)
VRTX,2021-09-13,12:14:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
VRTX,2021-09-17,20:19:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Canadian News Wire,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
VRTX,2021-09-17,20:21:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA
VRTX,2021-09-22,15:16:52,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-09-22,15:16:53,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kalydeco(R) (ivacaftor) has been accepted for priority review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,11:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes"
VRTX,2021-10-18,14:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration >MTEM
VRTX,2021-10-18,14:27:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,partnerships,terminated,Molecular Templates: Vertex Terminates Collaboration,RNS-SEC8K,Dow Jones Newswires,Molecular Templates: Vertex Terminates Collaboration
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Business Wire,Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: 96-week interim results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-19,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
VRTX,2021-10-20,08:30:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2021 (VRTX)"
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third-Quarter 2021 Financial Results on November 2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-22,12:03:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third-Quarter 2021 Financial Results on November 2
VRTX,2021-10-26,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:00:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Mammoth Biosciences Announce Collaboration to Develop in Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-26,13:06:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Mammoth Biosciences Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
VRTX,2021-10-27,16:07:11,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Canadian News Wire,Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-10-27,16:07:12,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) has been accepted for Priority Review by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex's Supplement to a New Drug Submission for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.28,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.28 >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $851.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $851.9M >VRTX
VRTX,2021-11-02,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $1.98B >VRTX
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Third-Quarter 2021 Financial -4-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP net income $ 852 $ 667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $1.98 billion, a 29% increase compared to Q3 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Phase 2 clinical results for VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals Inc.: we are again raising our 2021 product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: We completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.28 $ 2.53,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenues in the third quarter of 2021 increased 13%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $7.4 to 7.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Kalydeco (ivacaftor) will also be presented at the conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 Financial Results
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex expects to submit an IND,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"October, Vertex announced a new collaboration with Mammoth Biosciences",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 851,928 $667,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.30 $ 2.56 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -2-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 925,759 $697,346",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: GAAP total revenues $1,984,164 $1,538,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $1,984,164 $1,536,271",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 236,512 $ 186,182 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,90,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 12,618,745 $ 11,751,808",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -3-
VRTX,2021-11-02,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third-Quarter 2021 -4-
VRTX,2021-11-02,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Raises Full-Year 2021 Guidance for Product Revenue to $7.4 Billion to $7.5 Billion >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,03:30:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q3-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Reshma Kewalramani on Q3 2021 Results -- Earnings Call Transcript >VRTX
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-11-03,13:05:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $250.00/Share From $246.00 by RBC Capital
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Vertex Pharmaceuticals Inc.: the company beat third-quarter earnings expectations,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.46,revenues,up,"Vertex Pharmaceuticals Inc.: The company reported product revenue of $2 billion, up 29%",FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,14:33:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex increased its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Is Climbing After Strong Earnings, but the Competition Hasn't Gone Away. -- Barrons.com"
VRTX,2021-11-03,20:15:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-12,12:27:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-12,12:27:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
VRTX,2021-11-16,21:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-16,21:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 51 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 51 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Neutral From Overweight by Piper Sandler
VRTX,2021-11-19,10:03:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $218.00/Share From $323.00 by Piper Sandler
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by BMO Capital
VRTX,2021-11-19,10:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $202.00/Share by BMO Capital
VRTX,2021-11-19,11:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,11:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Spain for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
VRTX,2021-11-19,13:53:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals started at market perform with $202 stock price target at BMO Capital
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 -2-
VRTX,2021-12-01,12:30:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:31:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-01,12:37:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex to hold a conference call on these results today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
VRTX,2021-12-02,12:38:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Wells Fargo
VRTX,2021-12-09,13:38:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $270.00/Share by Wells Fargo
VRTX,2022-01-04,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-08,02:05:16,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"In December, Vertex reported positive results from a Phase 2 trial",FULL-ARTICLE,Dow Jones Newswires,Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out. -- Barrons.com
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital
VRTX,2022-01-20,13:23:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to outperform at BMO Capital
VRTX,2022-01-21,08:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)"
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.00,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.00 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.37,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.37 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $770.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $770.1M >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -5-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -5-
VRTX,2022-01-26,21:04:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-01,21:10:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital
VRTX,2022-02-03,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:21:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:27:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"CFO Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-14,21:21:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:30:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:31:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,21:31:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:35:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:50:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:02:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 290 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 290 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:18:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-16,21:07:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,21:55:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:07:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:07:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:10:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 519 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 519 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:42:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:44:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 325 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 325 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-28,22:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:09:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-01,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8
VRTX,2022-03-01,21:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-21,20:11:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:14:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Business Wire,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,NEWS-FLASH,Dow Jones Newswires,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-26,21:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-29,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: We are proud to partner with Vertex on,PRESS-RELEASE,GlobeNewswire,American Kidney Fund Announces Support from Vertex Pharmaceuticals Inc. to Raise Awareness and Increase Education of the APOL1 Gene and its Link to Kidney Disease
VRTX,2022-03-31,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-03-31,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-04-04,20:07:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo
VRTX,2022-04-05,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:11:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-06,21:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-06,21:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-08,20:36:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 561 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 561 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-08,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:07:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-13,13:36:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS
VRTX,2022-04-14,20:36:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-14,20:36:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-18,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-20,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-21,07:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)"
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler
VRTX,2022-04-27,20:07:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 327 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 327 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Provides Updates on Phase 1/2 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:35:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold in U.S. by FDA
VRTX,2022-05-02,14:55:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex reports first-quarter earnings on May 5,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Falls as FDA Places Clinical Hold on Diabetes Treatment -- Barrons.com
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley
VRTX,2022-05-03,20:30:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 120 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 120 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:08:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:11:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:22:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.96,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.96 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.52 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:02:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-05-06,01:15:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript >VRTX
VRTX,2022-05-06,20:08:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Suketu Upadhyay Elected to Vertex Board of Directors
VRTX,2022-05-18,14:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Suketu Upadhyay Elected to Vertex Bd of Directors
VRTX,2022-05-18,20:20:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:22:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:23:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-06-01,12:15:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group
VRTX,2022-06-02,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation By U.S. FDA,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation By U.S. FDA And Priority Medicines (PRIME) Designation By The EMA >VRTX
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Business Wire,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex Pharmaceuticals Inc.: the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
VRTX,2022-06-10,15:00:31,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2022-06-11,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2022-06-11,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics -2-
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.2,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research
VRTX,2022-06-28,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-05,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Announces FDA Has Lifted The Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Has Lifted The Clinical Hold On VX-880 Phase 1/2 Clinical Trial For The Treatment Of Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:15:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes
VRTX,2022-07-06,17:27:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex To Acquire ViaCyte,NEWS-FLASH,Dow Jones Newswires,"Vertex To Acquire ViaCyte, With The Goal Of Accelerating Its Potentially Curative VX-880 Programs In Type 1 Diabetes >VRTX"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire ViaCyte for $320 million in cash,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:02:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte for $320M in Cash,NEWS-FLASH,Dow Jones Newswires,Vertex to Acquire ViaCyte for $320M in Cash >VRTX
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,GlobeNewswire,Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-21,07:17:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)"
VRTX,2022-07-21,20:50:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Business Wire,Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler
VRTX,2022-07-27,19:03:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-27,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-02,20:17:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-03,17:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-03,20:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -5-
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The VX-880 Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -5-
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B >VRTX
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley
VRTX,2022-08-10,20:09:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 946 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,20:11:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,22:18:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:09:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,19:23:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:37:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 3,747 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:41:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:11:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:14:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,17:41:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:14:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:23:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Business Wire,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For ORKAMBI(R) (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 12 To <24 Months >VRTX
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) -2-
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-02,18:04:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-08,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Jonathan Biller as Chief Legal Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-08,13:11:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-12,11:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523),PRESS-RELEASE,PR Newswire,"BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine"
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:02:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Initiates First-In-Human Trial of,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiates First-In-Human Trial of Next-Wave AAT Corrector VX-634 >VRTX
VRTX,2022-10-11,12:08:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to Launch Phase 2 Study Evaluating,NEWS-FLASH,Dow Jones Newswires,Vertex to Launch Phase 2 Study Evaluating Impact of Longer-Term Treatment With VX-864 >VRTX
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-19,18:42:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-20,20:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-21,07:24:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)"
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan
VRTX,2022-10-25,15:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-26,20:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -4-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $930.5M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $930.5M >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -4-
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $931M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $931M >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B >VRTX
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.36,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays
VRTX,2022-11-03,12:00:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,12:00:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,20:03:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-03,20:07:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-04,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to,PRESS-RELEASE,Business Wire,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-04,12:07:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-08,21:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,21:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-16,20:48:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research
VRTX,2022-11-17,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-12-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
VRTX,2022-12-08,12:00:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.38,labor-issues,,Vertex Pharmaceuticals Inc.: Wren Taps Vertex Veteran,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: He has developed novel equipment,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,18:34:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-08,18:49:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-10,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies
VRTX,2022-01-04,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-08,02:05:16,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"In December, Vertex reported positive results from a Phase 2 trial",FULL-ARTICLE,Dow Jones Newswires,Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out. -- Barrons.com
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital
VRTX,2022-01-20,13:23:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to outperform at BMO Capital
VRTX,2022-01-21,08:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)"
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.00,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.00 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.37,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.37 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $770.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $770.1M >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -5-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -5-
VRTX,2022-01-26,21:04:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-01,21:10:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital
VRTX,2022-02-03,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:21:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:27:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"CFO Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-14,21:21:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:30:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:31:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,21:31:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:35:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:50:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:02:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 290 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 290 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:18:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-16,21:07:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,21:55:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:07:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:07:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:10:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 519 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 519 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:42:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:44:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 325 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 325 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-28,22:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:09:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-01,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8
VRTX,2022-03-01,21:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-21,20:11:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:14:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Business Wire,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,NEWS-FLASH,Dow Jones Newswires,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-26,21:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-29,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: We are proud to partner with Vertex on,PRESS-RELEASE,GlobeNewswire,American Kidney Fund Announces Support from Vertex Pharmaceuticals Inc. to Raise Awareness and Increase Education of the APOL1 Gene and its Link to Kidney Disease
VRTX,2022-03-31,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-03-31,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-04-04,20:07:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo
VRTX,2022-04-05,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:11:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-06,21:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-06,21:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-08,20:36:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 561 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 561 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-08,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:07:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-13,13:36:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS
VRTX,2022-04-14,20:36:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-14,20:36:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-18,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-20,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-21,07:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)"
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler
VRTX,2022-04-27,20:07:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 327 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 327 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Provides Updates on Phase 1/2 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:35:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold in U.S. by FDA
VRTX,2022-05-02,14:55:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex reports first-quarter earnings on May 5,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Falls as FDA Places Clinical Hold on Diabetes Treatment -- Barrons.com
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley
VRTX,2022-05-03,20:30:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 120 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 120 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:08:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:11:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:22:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.96,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.96 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.52 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:02:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-05-06,01:15:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript >VRTX
VRTX,2022-05-06,20:08:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Suketu Upadhyay Elected to Vertex Board of Directors
VRTX,2022-05-18,14:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Suketu Upadhyay Elected to Vertex Bd of Directors
VRTX,2022-05-18,20:20:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:22:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:23:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-06-01,12:15:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group
VRTX,2022-06-02,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation By U.S. FDA,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation By U.S. FDA And Priority Medicines (PRIME) Designation By The EMA >VRTX
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Business Wire,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex Pharmaceuticals Inc.: the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
VRTX,2022-06-10,15:00:31,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2022-06-11,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2022-06-11,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics -2-
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.2,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research
VRTX,2022-06-28,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-05,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Announces FDA Has Lifted The Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Has Lifted The Clinical Hold On VX-880 Phase 1/2 Clinical Trial For The Treatment Of Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:15:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes
VRTX,2022-07-06,17:27:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex To Acquire ViaCyte,NEWS-FLASH,Dow Jones Newswires,"Vertex To Acquire ViaCyte, With The Goal Of Accelerating Its Potentially Curative VX-880 Programs In Type 1 Diabetes >VRTX"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire ViaCyte for $320 million in cash,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:02:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte for $320M in Cash,NEWS-FLASH,Dow Jones Newswires,Vertex to Acquire ViaCyte for $320M in Cash >VRTX
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,GlobeNewswire,Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-21,07:17:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)"
VRTX,2022-07-21,20:50:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Business Wire,Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler
VRTX,2022-07-27,19:03:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-27,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-02,20:17:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-03,17:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-03,20:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -5-
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The VX-880 Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -5-
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B >VRTX
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley
VRTX,2022-08-10,20:09:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 946 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,20:11:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,22:18:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:09:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,19:23:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:37:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 3,747 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:41:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:11:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:14:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,17:41:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:14:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:23:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Business Wire,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For ORKAMBI(R) (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 12 To <24 Months >VRTX
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) -2-
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-02,18:04:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-08,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Jonathan Biller as Chief Legal Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-08,13:11:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-12,11:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523),PRESS-RELEASE,PR Newswire,"BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine"
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:02:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Initiates First-In-Human Trial of,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiates First-In-Human Trial of Next-Wave AAT Corrector VX-634 >VRTX
VRTX,2022-10-11,12:08:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to Launch Phase 2 Study Evaluating,NEWS-FLASH,Dow Jones Newswires,Vertex to Launch Phase 2 Study Evaluating Impact of Longer-Term Treatment With VX-864 >VRTX
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-19,18:42:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-20,20:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-21,07:24:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)"
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan
VRTX,2022-10-25,15:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-26,20:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -4-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $930.5M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $930.5M >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -4-
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $931M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $931M >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B >VRTX
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.36,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays
VRTX,2022-11-03,12:00:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,12:00:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,20:03:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-03,20:07:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-04,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to,PRESS-RELEASE,Business Wire,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-04,12:07:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-08,21:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,21:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-16,20:48:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research
VRTX,2022-11-17,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-12-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
VRTX,2022-12-08,12:00:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.38,labor-issues,,Vertex Pharmaceuticals Inc.: Wren Taps Vertex Veteran,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: He has developed novel equipment,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,18:34:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-08,18:49:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-10,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies
VRTX,2022-01-04,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-08,02:05:16,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"In December, Vertex reported positive results from a Phase 2 trial",FULL-ARTICLE,Dow Jones Newswires,Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out. -- Barrons.com
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital
VRTX,2022-01-20,13:23:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to outperform at BMO Capital
VRTX,2022-01-21,08:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)"
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.00,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.00 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.37,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.37 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $770.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $770.1M >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -5-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -5-
VRTX,2022-01-26,21:04:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-01,21:10:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital
VRTX,2022-02-03,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:21:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:27:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"CFO Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-14,21:21:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:30:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:31:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,21:31:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:35:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:50:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:02:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 290 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 290 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:18:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-16,21:07:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,21:55:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:07:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:07:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:10:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 519 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 519 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:42:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:44:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 325 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 325 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-28,22:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:09:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-01,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8
VRTX,2022-03-01,21:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-21,20:11:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:14:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Business Wire,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,NEWS-FLASH,Dow Jones Newswires,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-26,21:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-29,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: We are proud to partner with Vertex on,PRESS-RELEASE,GlobeNewswire,American Kidney Fund Announces Support from Vertex Pharmaceuticals Inc. to Raise Awareness and Increase Education of the APOL1 Gene and its Link to Kidney Disease
VRTX,2022-03-31,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-03-31,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-04-04,20:07:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo
VRTX,2022-04-05,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:11:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-06,21:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-06,21:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-08,20:36:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 561 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 561 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-08,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:07:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-13,13:36:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS
VRTX,2022-04-14,20:36:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-14,20:36:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-18,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-20,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-21,07:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)"
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler
VRTX,2022-04-27,20:07:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 327 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 327 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Provides Updates on Phase 1/2 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:35:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold in U.S. by FDA
VRTX,2022-05-02,14:55:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex reports first-quarter earnings on May 5,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Falls as FDA Places Clinical Hold on Diabetes Treatment -- Barrons.com
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley
VRTX,2022-05-03,20:30:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 120 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 120 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:08:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:11:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:22:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.96,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.96 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.52 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:02:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-05-06,01:15:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript >VRTX
VRTX,2022-05-06,20:08:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Suketu Upadhyay Elected to Vertex Board of Directors
VRTX,2022-05-18,14:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Suketu Upadhyay Elected to Vertex Bd of Directors
VRTX,2022-05-18,20:20:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:22:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:23:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-06-01,12:15:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group
VRTX,2022-06-02,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation By U.S. FDA,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation By U.S. FDA And Priority Medicines (PRIME) Designation By The EMA >VRTX
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Business Wire,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex Pharmaceuticals Inc.: the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
VRTX,2022-06-10,15:00:31,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2022-06-11,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2022-06-11,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics -2-
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.2,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research
VRTX,2022-06-28,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-05,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Announces FDA Has Lifted The Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Has Lifted The Clinical Hold On VX-880 Phase 1/2 Clinical Trial For The Treatment Of Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:15:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes
VRTX,2022-07-06,17:27:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex To Acquire ViaCyte,NEWS-FLASH,Dow Jones Newswires,"Vertex To Acquire ViaCyte, With The Goal Of Accelerating Its Potentially Curative VX-880 Programs In Type 1 Diabetes >VRTX"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire ViaCyte for $320 million in cash,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:02:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte for $320M in Cash,NEWS-FLASH,Dow Jones Newswires,Vertex to Acquire ViaCyte for $320M in Cash >VRTX
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,GlobeNewswire,Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-21,07:17:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)"
VRTX,2022-07-21,20:50:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Business Wire,Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler
VRTX,2022-07-27,19:03:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-27,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-02,20:17:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-03,17:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-03,20:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -5-
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The VX-880 Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -5-
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B >VRTX
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley
VRTX,2022-08-10,20:09:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 946 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,20:11:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,22:18:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:09:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,19:23:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:37:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 3,747 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:41:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:11:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:14:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,17:41:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:14:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:23:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Business Wire,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For ORKAMBI(R) (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 12 To <24 Months >VRTX
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) -2-
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-02,18:04:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-08,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Jonathan Biller as Chief Legal Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-08,13:11:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-12,11:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523),PRESS-RELEASE,PR Newswire,"BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine"
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:02:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Initiates First-In-Human Trial of,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiates First-In-Human Trial of Next-Wave AAT Corrector VX-634 >VRTX
VRTX,2022-10-11,12:08:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to Launch Phase 2 Study Evaluating,NEWS-FLASH,Dow Jones Newswires,Vertex to Launch Phase 2 Study Evaluating Impact of Longer-Term Treatment With VX-864 >VRTX
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-19,18:42:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-20,20:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-21,07:24:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)"
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan
VRTX,2022-10-25,15:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-26,20:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -4-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $930.5M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $930.5M >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -4-
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $931M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $931M >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B >VRTX
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.36,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays
VRTX,2022-11-03,12:00:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,12:00:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,20:03:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-03,20:07:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-04,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to,PRESS-RELEASE,Business Wire,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-04,12:07:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-08,21:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,21:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-16,20:48:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research
VRTX,2022-11-17,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-12-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
VRTX,2022-12-08,12:00:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.38,labor-issues,,Vertex Pharmaceuticals Inc.: Wren Taps Vertex Veteran,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: He has developed novel equipment,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,18:34:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-08,18:49:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-10,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies
VRTX,2022-01-04,21:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 40(th) Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-04,21:29:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
VRTX,2022-01-08,02:05:16,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"In December, Vertex reported positive results from a Phase 2 trial",FULL-ARTICLE,Dow Jones Newswires,Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out. -- Barrons.com
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-10,17:21:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript >VRTX"
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-18,21:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital
VRTX,2022-01-20,10:00:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $274.00/Share From $202.00 by BMO Capital
VRTX,2022-01-20,13:23:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to outperform at BMO Capital
VRTX,2022-01-21,08:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2021 (VRTX)"
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.00,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.00 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.37,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.37 >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $770.1M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $770.1M >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.07B >VRTX
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -2-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -3-
VRTX,2022-01-26,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter 2021 and Full Year -5-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Reports Fourth Quarter 2021 and Full Year Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenues of $7.57 billion, a 22% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.00 $ 2.30,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income decreased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Inc.: Non-GAAP net income increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,"Vertex Pharmaceuticals Inc.: Combined GAAP R&D and SG&A expenses increased compared to 2020, primarily due to the $900 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.4 to $8.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: we secured additional reimbursement approvals for KAFTRIO(R) (ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 study of ORKAMBI in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is evaluating CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: we plan to submit an IND for this program in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -2-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Non-GAAP total revenues $2,072.6 $1,626.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 865.9 $ 660.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.02 $ 2.32 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,93,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 247.4 $ 203.1 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -3-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 13,432.5 $ 11,751.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -4-
VRTX,2022-01-26,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast today at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter 2021 -5-
VRTX,2022-01-26,21:04:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Provides Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:26:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceutical 4Q Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-26,21:41:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: The company reported full-year 2021 product revenue of $7.57 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-01-27,02:44:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-01,21:10:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
VRTX,2022-02-03,10:31:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $269.00/Share by RBC Capital
VRTX,2022-02-03,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 4,660 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:21:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,279 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:27:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sanna Sells 1,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-03,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"CFO Wagner Jr Sells 2,944 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-05,09:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q4 2021 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-02-14,21:21:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,040 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:27:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,437 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:30:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 3,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:31:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 474 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,21:31:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,491 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:35:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Altshuler Sells 2,297 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-14,21:50:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 979 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:02:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 290 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 290 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-14,22:18:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,434 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-16,21:07:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 2,444 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,21:55:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,312 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,126 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,584 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:06:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 8,236 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:07:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Surrenders 712 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:07:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,497 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:10:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 519 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 519 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-22,22:13:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-22,22:13:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,439 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:42:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:44:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 325 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 325 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-02-28,22:52:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Surrenders 1,554 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,22:53:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,189 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 7,246 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:06:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,368 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:09:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 7,572 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-02-28,23:16:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 12,141 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-01,21:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 42(nd) Annual Health Care Conference on March 8
VRTX,2022-03-01,21:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-08,23:16:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript) >VRTX"
VRTX,2022-03-21,20:11:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,122 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:14:06,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,171 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-21,20:16:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,833 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-03-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Business Wire,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-22,12:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Advances VX-147 Into Pivotal Clinical Development,NEWS-FLASH,Dow Jones Newswires,Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
VRTX,2022-03-26,21:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Business Wire,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-26,21:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Ivacaftor) was approved by the Australian Therapeutic Goods Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
VRTX,2022-03-29,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: We are proud to partner with Vertex on,PRESS-RELEASE,GlobeNewswire,American Kidney Fund Announces Support from Vertex Pharmaceuticals Inc. to Raise Awareness and Increase Education of the APOL1 Gene and its Link to Kidney Disease
VRTX,2022-03-31,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Business Wire,Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-03-31,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 2 Study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
VRTX,2022-04-04,20:07:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-04-05,12:42:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $270.00 by Wells Fargo
VRTX,2022-04-05,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,582 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:11:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-05,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 137 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-06,21:01:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-06,21:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 3,725 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-08,20:36:15,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 561 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 561 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-04-08,21:58:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:07:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir McGlynn Sells 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bhatia Sells 1,907 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-12,20:08:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-13,13:36:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $325 from $258 at UBS
VRTX,2022-04-14,20:36:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-14,20:36:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 15,789 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-18,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-20,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-04-21,07:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2022 (VRTX)"
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2022 Financial Results on May 5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-21,21:04:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2022 Financial Results on May 5
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-04-22,12:12:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $249.00/Share From $245.00 by Piper Sandler
VRTX,2022-04-27,20:07:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 327 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 327 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company also announced the VX-880 Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: The results from the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Results from Day,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Provides Updates on Phase 1/2 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
VRTX,2022-05-02,12:35:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: VX-880 Phase 1/2 Study Placed on Clinical Hold in U.S. by FDA
VRTX,2022-05-02,14:55:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex reports first-quarter earnings on May 5,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Falls as FDA Places Clinical Hold on Diabetes Treatment -- Barrons.com
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Equal-Weight From Underweight by Morgan Stanley
VRTX,2022-05-03,10:38:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $250.00/Share by Morgan Stanley
VRTX,2022-05-03,20:30:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 120 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 120 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-03,20:44:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Surrenders 547 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:08:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Wagner Jr Sells 343 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:11:55,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 737 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-04,21:22:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 306 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.96,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.96 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.52 >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.1B >VRTX
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2022 Financial -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.10 billion, a 22% increase compared to Q1 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762 $ 653,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 2.96 $ 2.49,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,equity-actions,up,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses increased,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted marketing authorization for TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 Financial Results
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CF mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex Pharmaceuticals Inc.: Enrollment is complete,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex anticipates presenting updated data from the clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.54,products-services,suspended,Vertex Pharmaceuticals Inc.: This program has been placed on clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -2-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 762.1 $ 653.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.99 $ 2.52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,97,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $ 245.8 $ 192.3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -3-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 14,256.1 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 5: ""Acquisition-related costs"" in the three months ended March 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2022 -4-
VRTX,2022-05-05,20:02:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Reiterates Full Yr 2022 Pdt Rev Guidance of $8.4B to $8.6B >VRTX
VRTX,2022-05-06,01:15:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Incorporated CEO Dr. Reshma Kewalramani on Q1 2022 Results -- Earnings Call Transcript >VRTX
VRTX,2022-05-06,20:08:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,14:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Suketu Upadhyay Elected to Vertex Board of Directors
VRTX,2022-05-18,14:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Upadhyay Elected to Vertex Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Suketu Upadhyay Elected to Vertex Bd of Directors
VRTX,2022-05-18,20:20:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:22:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 133 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-18,20:23:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 45 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 45 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by SVB Leerink
VRTX,2022-05-23,10:07:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $265.00/Share by SVB Leerink
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to Present New Data on VX-880 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-05-31,12:11:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
VRTX,2022-06-01,12:15:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group,NEWS-FLASH,MarketWatch,MW Vertex Pharmaceuticals upgraded to buy from hold at Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Buy From Hold by Maxim Group
VRTX,2022-06-01,12:58:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $325.00/Share by Maxim Group
VRTX,2022-06-02,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress
VRTX,2022-06-02,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Bozic Surrenders 311 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: These results from the first,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-06,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82(nd) Scientific Sessions
VRTX,2022-06-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation By U.S. FDA,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation By U.S. FDA And Priority Medicines (PRIME) Designation By The EMA >VRTX
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Business Wire,Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vx-147) Granted Breakthrough Therapy Designation by U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex Pharmaceuticals Inc.: the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Participate in the Goldman Sachs 43(rd) Annual Healthcare Conference on June 15
VRTX,2022-06-08,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
VRTX,2022-06-10,15:00:31,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2022-06-11,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Present New Data -2-
VRTX,2022-06-11,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics -2-
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.2,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Cowen & Co.
VRTX,2022-06-13,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $310.00/Share From $305.00 by Cowen & Co.
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-06-13,12:51:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $280.00/Share From $275.00 by Argus Research
VRTX,2022-06-28,20:06:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-05,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Announces FDA Has Lifted The Clinical Hold,NEWS-FLASH,Dow Jones Newswires,Vertex Announces FDA Has Lifted The Clinical Hold On VX-880 Phase 1/2 Clinical Trial For The Treatment Of Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Business Wire,Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: About the Phase 1/2 Clinical Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
VRTX,2022-07-05,12:15:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes >VRTX
VRTX,2022-07-05,12:30:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,resumed,Vertex Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has lifted a clinical hold,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA Lifts Clinical Hold on VX-880 Study in Type 1 Diabetes
VRTX,2022-07-06,17:27:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex To Acquire ViaCyte,NEWS-FLASH,Dow Jones Newswires,"Vertex To Acquire ViaCyte, With The Goal Of Accelerating Its Potentially Curative VX-880 Programs In Type 1 Diabetes >VRTX"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Business Wire,"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex will acquire ViaCyte for $320 million in cash,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex to deploy ViaCyte's tools,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes"
VRTX,2022-07-11,12:02:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex to Acquire ViaCyte for $320M in Cash,NEWS-FLASH,Dow Jones Newswires,Vertex to Acquire ViaCyte for $320M in Cash >VRTX
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
VRTX,2022-07-13,10:04:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $365.00/Share by Cantor Fitzgerald
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2022 Financial Results on August 4,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-18,20:13:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2022 Financial Results on August 4
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,GlobeNewswire,Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-20,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Verve Therapeutics Establish Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
VRTX,2022-07-21,07:17:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2022 (VRTX)"
VRTX,2022-07-21,20:50:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-22,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Business Wire,Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-22,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Breakthrough Therapy Designation granted by FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances VX-548 in Acute and Neuropathic Pain
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2022-07-26,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $256.00/Share From $242.00 by Piper Sandler
VRTX,2022-07-27,19:03:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 17,865 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-07-27,20:19:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-02,20:17:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-03,17:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 132,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-03,20:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Surrenders 766 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -2-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -3-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -4-
VRTX,2022-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2022 Financial -5-
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:01:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenues of $2.20 billion, a 22% increase compared to Q2 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810 $ 67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.13 $ 0.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex's collaboration with CRISPR Therapeutics in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.6 to $8.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 Financial Results
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 3 study of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"April, Health Canada granted marketing authorization for TRIKAFTA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex initiated pivotal development of inaxaplin (VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -2-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The VX-880 Phase 1/2 clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Vertex Pharmaceuticals Inc.: In July, Vertex entered into a definitive agreement to acquire ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,"In July, Vertex entered into a research collaboration with Verve Therapeutics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,,"In May, Vertex acquired Catalyst Biosciences' complement portfolio",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 810.5 $ 67.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.17 $ 0.26 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -3-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $261.8 $ 228.0 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 15,582.2 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -4-
VRTX,2022-08-04,20:03:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2022 -5-
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.13,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.13 >VRTX
VRTX,2022-08-04,20:04:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.60,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.60 >VRTX
VRTX,2022-08-04,20:04:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.2B >VRTX
VRTX,2022-08-04,20:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises FY22 Pdt Rev Guidance to $8.6 B to $8.8 B >VRTX
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,00:37:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc. CEO Reshma Kewalramani on Q2 2022 Results -- Earnings Call Transcript >VRTX"
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-08-05,12:09:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $307.00/Share From $291.00 by Barclays
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2022-08-05,12:53:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $300.00/Share From $275.00 by HC Wainwright & Co.
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-08-08,14:38:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $253.00/Share From $250.00 by Morgan Stanley
VRTX,2022-08-10,20:09:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:10:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-10,20:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 946 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,20:11:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-10,22:18:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:07:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Liu Sells 36 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Liu Sells 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-12,20:09:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,19:23:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,690 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:37:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Liu Sells 3,747 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Liu Sells 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:40:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,21:41:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:11:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 36 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:14:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 180 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:24:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Liu Registers 946 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-08-17,22:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 1,400 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-17,22:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,17:41:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 22,173 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:14:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 11,689 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-24,18:23:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Liu Registers 3,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Business Wire,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-08-31,12:13:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,"Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9"
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For ORKAMBI(R) (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 12 To <24 Months >VRTX
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for ORKAMBI(R) -2-
VRTX,2022-09-02,17:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for ORKAMBI(R) (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
VRTX,2022-09-02,17:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-02,18:04:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc. said Friday the Food and Drug Administration has approved expanded use of Orkambi,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets FDA Approval for Cystic Fibrosis Drug Orkambi in Children
VRTX,2022-09-08,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Appoints Jonathan Biller as Chief Legal Officer,PRESS-RELEASE,Business Wire,Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-08,13:11:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.53,labor-issues,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Jonathan Biller as Chief Legal Officer
VRTX,2022-09-12,11:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523),PRESS-RELEASE,PR Newswire,"BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine"
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-09-27,11:29:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiates first-in-human trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:00:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
VRTX,2022-10-11,12:02:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Initiates First-In-Human Trial of,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiates First-In-Human Trial of Next-Wave AAT Corrector VX-634 >VRTX
VRTX,2022-10-11,12:08:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to Launch Phase 2 Study Evaluating,NEWS-FLASH,Dow Jones Newswires,Vertex to Launch Phase 2 Study Evaluating Impact of Longer-Term Treatment With VX-864 >VRTX
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2022 Financial Results on October 27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-13,20:09:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2022 Financial Results on October 27
VRTX,2022-10-19,18:42:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-20,20:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 1,791 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-10-21,07:24:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2022 (VRTX)"
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2022-10-24,14:52:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $327.00/Share From $319.00 by JP Morgan
VRTX,2022-10-25,15:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-26,20:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 621 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -2-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -3-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2022 Financial -4-
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $930.5M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $930.5M >VRTX
VRTX,2022-10-27,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.33B >VRTX
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.33 billion, an 18% increase compared to Q3 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Inc.: Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals Inc.: Initiated Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 931 $ 852,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.59 $ 3.28,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Product revenues $8.8 to $8.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: U.S. regulatory approval for ORKAMBI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Upcoming presentation of full results from the TRIKAFTA/KAFTRIO Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: In collaboration with Moderna, Vertex is developing a CFTR mRNA therapeutic to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 Financial Results
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex continues to enroll patients in Part B of the Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex will soon initiate a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex anticipates submitting an IND in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"On September 27, 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -2-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 930.5 $ 851.9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.63 $ 3.30 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: GAAP cost of sales $289.4 $236.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 16,706.4 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -3-
VRTX,2022-10-27,20:01:30,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2022 -4-
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.59,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.59 >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $931M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $931M >VRTX
VRTX,2022-10-27,20:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.01,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.01 >VRTX
VRTX,2022-10-27,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Increases Full Yr 2022 Pdt Rev Guidance to $8.8B to $8.9B >VRTX
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2022-10-28,12:15:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $335.00/Share From $305.00 by Wells Fargo
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2022-10-28,15:10:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $288.00/Share From $281.00 by RBC Capital
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2022-10-28,15:47:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $285.00/Share From $253.00 by Morgan Stanley
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2022-10-28,19:54:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.36,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $313.00/Share From $307.00 by Barclays
VRTX,2022-11-03,12:00:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,12:00:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex will present data from a pooled analysis from multiple Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
VRTX,2022-11-03,20:03:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-03,20:07:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-04,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to,PRESS-RELEASE,Business Wire,Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-04,12:07:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Inc.: the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
VRTX,2022-11-08,21:33:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,13:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2022-11-09,21:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,303 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2022-11-16,20:48:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2022-11-17,14:49:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $320.00 by Argus Research
VRTX,2022-11-17,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 34 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 34 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2022-12-08,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,PRESS-RELEASE,Business Wire,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
VRTX,2022-12-08,12:00:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex and Entrada Therapeutics Establish Collaboration to,NEWS-FLASH,Dow Jones Newswires,Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.38,labor-issues,,Vertex Pharmaceuticals Inc.: Wren Taps Vertex Veteran,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,13:30:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: He has developed novel equipment,PRESS-RELEASE,PR Newswire,Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
VRTX,2022-12-08,18:34:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-08,18:49:41,57CAAB,Vertex Pharmaceuticals Inc.,91,0.49,partnerships,,Entrada Therapeutics Inc.: the company will collaborate with Vertex Pharmaceuticals Inc. to,FULL-ARTICLE,Dow Jones Newswires,Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News
VRTX,2022-12-10,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Business Wire,"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex Pharmaceuticals Inc.: VX-522 clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: The partnership with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-12,13:06:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: Per Vertex's agreement with Moderna,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA"
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Hold From Buy by Jefferies
VRTX,2022-12-19,11:08:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $340.00/Share by Jefferies
VRTX,2023-01-04,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-11,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex,PRESS-RELEASE,GlobeNewswire,"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase"
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity
VRTX,2023-01-18,19:54:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler
VRTX,2023-01-19,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-01-19,21:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-20,09:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)"
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley
VRTX,2023-01-24,19:27:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,17:48:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,21:09:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:37:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:14:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,14:39:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,19:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,19:55:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:43:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,22:52:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,23:04:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-02,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-02,21:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 106 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-03,22:39:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-03,22:55:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.15,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.15 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.76 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: Share Repurchase Program,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex completed enrollment in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -5-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $818.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $818.9M >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2023-02-07,21:03:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program, Authorizing Repurchase of Up to $3.0B of Common Stk, Program Does Not Have Expiration Date and Can Be Discontinued at Any Time >VRTX"
VRTX,2023-02-07,21:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev Guidance of $9.55B to $9.7B >VRTX
VRTX,2023-02-07,21:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3B Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3B Share Repurchase Program
VRTX,2023-02-07,21:13:36,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.76 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,21:22:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.44,earnings,up,Vertex earnings rocketed 25% to $3.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:12:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays
VRTX,2023-02-08,14:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.59,equity-actions,up,Vertex projected higher-than-expected operating expenses for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:58:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,21:59:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:12:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 113 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:17:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 275 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:42:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:46:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-16,21:12:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:15:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:17:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:20:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-21,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7
VRTX,2023-02-21,21:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7
VRTX,2023-02-22,19:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:49:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,21:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:33:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:53:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,22:03:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:12:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:16:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:18:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-23,20:54:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-24,21:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,12:38:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Biosciences announces collaboration with Vertex to,PRESS-RELEASE,PR Newswire,Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
VRTX,2023-02-28,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:31:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:47:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:56:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,22:01:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,23:41:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:42:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:52:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:54:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-01,00:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-264, A Novel Encapsulated Cell Therapy For The Treatment Of Type 1 Diabetes >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months >VRTX
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-10,21:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-13,20:21:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-14,20:25:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,21:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-17,17:09:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-20,20:27:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Bernstein
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein
VRTX,2023-03-21,20:22:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-24,16:03:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:01:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,NEWS-FLASH,Dow Jones Newswires,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for Treatment of Type 1 Diabetes
VRTX,2023-03-28,20:17:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research
VRTX,2023-04-03,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-03,12:00:45,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-04,20:45:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-04,21:19:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-04,21:37:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,20:25:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 522 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,21:27:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,labor-issues,,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M >VRTX"
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,14:16:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI,PRESS-RELEASE,Canadian News Wire,Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Health Canada Market Authorization for Orkambi in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:19:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi Treatment in Pediatric Cystic Fibrosis >VRTX
VRTX,2023-04-10,14:46:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-10,15:01:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-12,20:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-12,21:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:21:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-20,08:23:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)"
VRTX,2023-04-25,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-25,12:02:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations >VRTX
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets FDA OK of Trikafta,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA OK of Trikafta in Children 2-5 With Cystic Fibrosis With Certain Mutations >VRTX
VRTX,2023-04-26,18:03:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-26,18:18:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-27,20:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.69,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.69 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.05,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.05 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $699.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $699.8M >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:05:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.05 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.1 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,unchanged,Vertex reiterated its guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:27:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Baird
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel
VRTX,2023-05-02,12:29:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.54,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $456,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $456 from $341 at Truist
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities
VRTX,2023-05-02,14:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-02,20:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-02,21:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein
VRTX,2023-05-03,20:39:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,20:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor) To Treat Eligible Infants With CF Ages 1 Month And Older >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler
VRTX,2023-05-04,20:53:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,20:56:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-05,20:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-05,21:15:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-08,19:15:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-08,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-09,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-30,10:10:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by William Blair
VRTX,2023-05-30,12:02:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
VRTX,2023-05-30,14:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:13:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 289 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 289 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital
VRTX,2023-06-08,23:29:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex: FDA Granted Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex: FDA Granted Priority Review for SCD and Standard Review for TDT and Assigned Prescription Drug User Fee Act Target Action Dates of Dec 8, 2023, and March 30, 2024, Respectively >VRTX"
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-15,20:33:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-20,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Presents Positive VX-880,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From -2-
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:33:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and Lonza Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and Lonza Collaboration to Support the Manufacture of Vertex's Portfolio of Investigational Stem Cell-Derived, Fully Differentiated Insulin-Producing Islet Cell Therapies for People With T1D >VRTX"
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group
VRTX,2023-06-29,14:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Trading Halt - VRTX,PRESS-RELEASE,Canadian News Wire,Canadian Investment Regulatory Organization Trading Halt - VRTX
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,13:20:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-03,12:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Business Wire,European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old >VRTX
VRTX,2023-07-17,16:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-17,17:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:18:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities
VRTX,2023-07-21,19:24:43,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-07-21,21:30:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.52 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.89,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.89 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $915.7M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $915.7M >VRTX
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -5-
VRTX,2023-08-01,20:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -5-
VRTX,2023-08-01,20:01:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B >VRTX
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.2 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity
VRTX,2023-08-09,14:18:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-09,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-10,14:54:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:09:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:54:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-11,20:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 63 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-11,20:06:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-14,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-19,07:23:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)"
VRTX,2023-08-23,16:39:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-25,20:16:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-30,20:01:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
VRTX,2023-09-05,19:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-07,20:30:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Business Wire,Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,13:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-15,13:24:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-19,13:57:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-21,20:16:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital
VRTX,2023-10-02,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,15:15:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-03,20:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 610 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-05,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Michel Lagarde to Its Bd of Directors
VRTX,2023-10-05,20:31:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-06,18:57:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-11,20:15:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-16,20:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,14:57:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,15:03:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA(R) (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:47:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) in Children With Cystic Fibrosis Ages 2 to 5 Years With at Least One F508del Mutation
VRTX,2023-10-17,19:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-17,19:15:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-18,20:18:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-19,20:14:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-19,20:19:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-26,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-26,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-31,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Business Wire,Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,20:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,16:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.97,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.97 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.08 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.04B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.04B >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -4-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -4-
VRTX,2023-11-06,21:01:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Leader Vertex Boosts Outlook After,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals (VRTX) reported third-quarter adjusted earnings of $4.08 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.65,revenues,up,Vertex said the revenue gains,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.7,earnings,up,Vertex raised its full-year guidance for,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital
VRTX,2023-11-08,21:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley
VRTX,2023-11-13,14:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Lab Design Tool Partners With Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Lab Design Tool Partners With Vertex Pharmaceuticals and LabOps Unite at Lab Asset & Facility Management (LAFM) 2023
VRTX,2023-11-13,20:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-14,17:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-15,15:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,15:33:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,21:17:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-16,06:45:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Business Wire,"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,06:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,21:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-17,21:17:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 19 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-17,21:26:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 35 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-19,08:35:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)"
VRTX,2023-11-20,16:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,DGAP News,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,Dow Jones Newswires,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,21:18:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in -2-
VRTX,2023-11-23,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:24:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-23,14:39:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-12-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX
VRTX,2023-12-08,16:16:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,16:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,17:04:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,18:26:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-09,12:47:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,Vertex Pharmaceuticals reported positive Phase 2 study results,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a Phase 2 study of VX-548,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement,NEWS-FLASH,Dow Jones Newswires,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement for Cas9
VRTX,2023-12-13,14:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,14:34:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,17:18:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,17:33:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,19:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,20:24:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,21:34:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital
VRTX,2023-12-15,17:54:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:23:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-18,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,94,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Business Wire,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,13:00:20,57CAAB,Vertex Pharmaceuticals Inc.,95,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,21:05:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
VRTX,2023-12-19,21:18:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-04,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-11,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex,PRESS-RELEASE,GlobeNewswire,"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase"
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity
VRTX,2023-01-18,19:54:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler
VRTX,2023-01-19,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-01-19,21:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-20,09:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)"
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley
VRTX,2023-01-24,19:27:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,17:48:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,21:09:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:37:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:14:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,14:39:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,19:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,19:55:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:43:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,22:52:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,23:04:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-02,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-02,21:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 106 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-03,22:39:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-03,22:55:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.15,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.15 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.76 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: Share Repurchase Program,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex completed enrollment in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -5-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $818.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $818.9M >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2023-02-07,21:03:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program, Authorizing Repurchase of Up to $3.0B of Common Stk, Program Does Not Have Expiration Date and Can Be Discontinued at Any Time >VRTX"
VRTX,2023-02-07,21:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev Guidance of $9.55B to $9.7B >VRTX
VRTX,2023-02-07,21:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3B Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3B Share Repurchase Program
VRTX,2023-02-07,21:13:36,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.76 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,21:22:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.44,earnings,up,Vertex earnings rocketed 25% to $3.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:12:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays
VRTX,2023-02-08,14:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.59,equity-actions,up,Vertex projected higher-than-expected operating expenses for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:58:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,21:59:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:12:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 113 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:17:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 275 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:42:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:46:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-16,21:12:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:15:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:17:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:20:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-21,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7
VRTX,2023-02-21,21:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7
VRTX,2023-02-22,19:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:49:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,21:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:33:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:53:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,22:03:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:12:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:16:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:18:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-23,20:54:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-24,21:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,12:38:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Biosciences announces collaboration with Vertex to,PRESS-RELEASE,PR Newswire,Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
VRTX,2023-02-28,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:31:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:47:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:56:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,22:01:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,23:41:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:42:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:52:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:54:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-01,00:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-264, A Novel Encapsulated Cell Therapy For The Treatment Of Type 1 Diabetes >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months >VRTX
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-10,21:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-13,20:21:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-14,20:25:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,21:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-17,17:09:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-20,20:27:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Bernstein
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein
VRTX,2023-03-21,20:22:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-24,16:03:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:01:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,NEWS-FLASH,Dow Jones Newswires,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for Treatment of Type 1 Diabetes
VRTX,2023-03-28,20:17:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research
VRTX,2023-04-03,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-03,12:00:45,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-04,20:45:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-04,21:19:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-04,21:37:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,20:25:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 522 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,21:27:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,labor-issues,,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M >VRTX"
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,14:16:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI,PRESS-RELEASE,Canadian News Wire,Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Health Canada Market Authorization for Orkambi in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:19:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi Treatment in Pediatric Cystic Fibrosis >VRTX
VRTX,2023-04-10,14:46:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-10,15:01:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-12,20:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-12,21:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:21:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-20,08:23:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)"
VRTX,2023-04-25,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-25,12:02:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations >VRTX
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets FDA OK of Trikafta,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA OK of Trikafta in Children 2-5 With Cystic Fibrosis With Certain Mutations >VRTX
VRTX,2023-04-26,18:03:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-26,18:18:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-27,20:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.69,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.69 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.05,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.05 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $699.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $699.8M >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:05:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.05 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.1 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,unchanged,Vertex reiterated its guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:27:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Baird
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel
VRTX,2023-05-02,12:29:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.54,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $456,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $456 from $341 at Truist
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities
VRTX,2023-05-02,14:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-02,20:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-02,21:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein
VRTX,2023-05-03,20:39:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,20:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor) To Treat Eligible Infants With CF Ages 1 Month And Older >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler
VRTX,2023-05-04,20:53:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,20:56:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-05,20:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-05,21:15:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-08,19:15:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-08,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-09,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-30,10:10:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by William Blair
VRTX,2023-05-30,12:02:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
VRTX,2023-05-30,14:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:13:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 289 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 289 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital
VRTX,2023-06-08,23:29:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex: FDA Granted Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex: FDA Granted Priority Review for SCD and Standard Review for TDT and Assigned Prescription Drug User Fee Act Target Action Dates of Dec 8, 2023, and March 30, 2024, Respectively >VRTX"
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-15,20:33:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-20,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Presents Positive VX-880,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From -2-
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:33:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and Lonza Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and Lonza Collaboration to Support the Manufacture of Vertex's Portfolio of Investigational Stem Cell-Derived, Fully Differentiated Insulin-Producing Islet Cell Therapies for People With T1D >VRTX"
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group
VRTX,2023-06-29,14:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Trading Halt - VRTX,PRESS-RELEASE,Canadian News Wire,Canadian Investment Regulatory Organization Trading Halt - VRTX
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,13:20:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-03,12:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Business Wire,European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old >VRTX
VRTX,2023-07-17,16:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-17,17:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:18:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities
VRTX,2023-07-21,19:24:43,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-07-21,21:30:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.52 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.89,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.89 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $915.7M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $915.7M >VRTX
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -5-
VRTX,2023-08-01,20:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -5-
VRTX,2023-08-01,20:01:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B >VRTX
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.2 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity
VRTX,2023-08-09,14:18:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-09,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-10,14:54:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:09:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:54:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-11,20:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 63 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-11,20:06:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-14,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-19,07:23:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)"
VRTX,2023-08-23,16:39:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-25,20:16:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-30,20:01:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
VRTX,2023-09-05,19:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-07,20:30:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Business Wire,Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,13:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-15,13:24:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-19,13:57:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-21,20:16:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital
VRTX,2023-10-02,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,15:15:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-03,20:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 610 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-05,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Michel Lagarde to Its Bd of Directors
VRTX,2023-10-05,20:31:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-06,18:57:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-11,20:15:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-16,20:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,14:57:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,15:03:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA(R) (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:47:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) in Children With Cystic Fibrosis Ages 2 to 5 Years With at Least One F508del Mutation
VRTX,2023-10-17,19:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-17,19:15:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-18,20:18:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-19,20:14:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-19,20:19:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-26,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-26,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-31,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Business Wire,Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,20:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,16:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.97,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.97 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.08 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.04B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.04B >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -4-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -4-
VRTX,2023-11-06,21:01:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Leader Vertex Boosts Outlook After,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals (VRTX) reported third-quarter adjusted earnings of $4.08 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.65,revenues,up,Vertex said the revenue gains,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.7,earnings,up,Vertex raised its full-year guidance for,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital
VRTX,2023-11-08,21:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley
VRTX,2023-11-13,14:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Lab Design Tool Partners With Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Lab Design Tool Partners With Vertex Pharmaceuticals and LabOps Unite at Lab Asset & Facility Management (LAFM) 2023
VRTX,2023-11-13,20:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-14,17:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-15,15:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,15:33:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,21:17:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-16,06:45:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Business Wire,"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,06:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,21:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-17,21:17:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 19 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-17,21:26:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 35 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-19,08:35:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)"
VRTX,2023-11-20,16:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,DGAP News,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,Dow Jones Newswires,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,21:18:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in -2-
VRTX,2023-11-23,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:24:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-23,14:39:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-12-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX
VRTX,2023-12-08,16:16:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,16:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,17:04:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,18:26:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-09,12:47:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,Vertex Pharmaceuticals reported positive Phase 2 study results,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a Phase 2 study of VX-548,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement,NEWS-FLASH,Dow Jones Newswires,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement for Cas9
VRTX,2023-12-13,14:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,14:34:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,17:18:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,17:33:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,19:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,20:24:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,21:34:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital
VRTX,2023-12-15,17:54:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:23:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-18,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,94,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Business Wire,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,13:00:20,57CAAB,Vertex Pharmaceuticals Inc.,95,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,21:05:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
VRTX,2023-12-19,21:18:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-04,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-11,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex,PRESS-RELEASE,GlobeNewswire,"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase"
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity
VRTX,2023-01-18,19:54:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler
VRTX,2023-01-19,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-01-19,21:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-20,09:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)"
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley
VRTX,2023-01-24,19:27:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,17:48:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,21:09:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:37:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:14:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,14:39:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,19:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,19:55:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:43:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,22:52:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,23:04:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-02,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-02,21:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 106 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-03,22:39:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-03,22:55:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.15,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.15 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.76 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: Share Repurchase Program,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex completed enrollment in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -5-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $818.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $818.9M >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2023-02-07,21:03:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program, Authorizing Repurchase of Up to $3.0B of Common Stk, Program Does Not Have Expiration Date and Can Be Discontinued at Any Time >VRTX"
VRTX,2023-02-07,21:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev Guidance of $9.55B to $9.7B >VRTX
VRTX,2023-02-07,21:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3B Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3B Share Repurchase Program
VRTX,2023-02-07,21:13:36,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.76 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,21:22:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.44,earnings,up,Vertex earnings rocketed 25% to $3.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:12:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays
VRTX,2023-02-08,14:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.59,equity-actions,up,Vertex projected higher-than-expected operating expenses for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:58:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,21:59:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:12:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 113 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:17:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 275 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:42:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:46:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-16,21:12:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:15:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:17:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:20:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-21,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7
VRTX,2023-02-21,21:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7
VRTX,2023-02-22,19:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:49:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,21:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:33:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:53:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,22:03:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:12:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:16:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:18:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-23,20:54:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-24,21:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,12:38:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Biosciences announces collaboration with Vertex to,PRESS-RELEASE,PR Newswire,Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
VRTX,2023-02-28,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:31:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:47:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:56:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,22:01:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,23:41:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:42:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:52:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:54:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-01,00:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-264, A Novel Encapsulated Cell Therapy For The Treatment Of Type 1 Diabetes >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months >VRTX
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-10,21:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-13,20:21:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-14,20:25:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,21:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-17,17:09:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-20,20:27:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Bernstein
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein
VRTX,2023-03-21,20:22:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-24,16:03:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:01:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,NEWS-FLASH,Dow Jones Newswires,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for Treatment of Type 1 Diabetes
VRTX,2023-03-28,20:17:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research
VRTX,2023-04-03,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-03,12:00:45,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-04,20:45:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-04,21:19:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-04,21:37:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,20:25:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 522 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,21:27:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,labor-issues,,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M >VRTX"
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,14:16:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI,PRESS-RELEASE,Canadian News Wire,Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Health Canada Market Authorization for Orkambi in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:19:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi Treatment in Pediatric Cystic Fibrosis >VRTX
VRTX,2023-04-10,14:46:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-10,15:01:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-12,20:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-12,21:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:21:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-20,08:23:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)"
VRTX,2023-04-25,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-25,12:02:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations >VRTX
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets FDA OK of Trikafta,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA OK of Trikafta in Children 2-5 With Cystic Fibrosis With Certain Mutations >VRTX
VRTX,2023-04-26,18:03:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-26,18:18:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-27,20:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.69,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.69 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.05,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.05 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $699.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $699.8M >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:05:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.05 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.1 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,unchanged,Vertex reiterated its guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:27:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Baird
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel
VRTX,2023-05-02,12:29:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.54,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $456,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $456 from $341 at Truist
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities
VRTX,2023-05-02,14:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-02,20:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-02,21:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein
VRTX,2023-05-03,20:39:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,20:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor) To Treat Eligible Infants With CF Ages 1 Month And Older >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler
VRTX,2023-05-04,20:53:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,20:56:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-05,20:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-05,21:15:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-08,19:15:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-08,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-09,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-30,10:10:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by William Blair
VRTX,2023-05-30,12:02:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
VRTX,2023-05-30,14:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:13:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 289 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 289 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital
VRTX,2023-06-08,23:29:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex: FDA Granted Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex: FDA Granted Priority Review for SCD and Standard Review for TDT and Assigned Prescription Drug User Fee Act Target Action Dates of Dec 8, 2023, and March 30, 2024, Respectively >VRTX"
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-15,20:33:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-20,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Presents Positive VX-880,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From -2-
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:33:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and Lonza Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and Lonza Collaboration to Support the Manufacture of Vertex's Portfolio of Investigational Stem Cell-Derived, Fully Differentiated Insulin-Producing Islet Cell Therapies for People With T1D >VRTX"
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group
VRTX,2023-06-29,14:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Trading Halt - VRTX,PRESS-RELEASE,Canadian News Wire,Canadian Investment Regulatory Organization Trading Halt - VRTX
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,13:20:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-03,12:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Business Wire,European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old >VRTX
VRTX,2023-07-17,16:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-17,17:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:18:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities
VRTX,2023-07-21,19:24:43,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-07-21,21:30:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.52 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.89,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.89 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $915.7M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $915.7M >VRTX
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -5-
VRTX,2023-08-01,20:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -5-
VRTX,2023-08-01,20:01:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B >VRTX
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.2 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity
VRTX,2023-08-09,14:18:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-09,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-10,14:54:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:09:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:54:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-11,20:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 63 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-11,20:06:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-14,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-19,07:23:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)"
VRTX,2023-08-23,16:39:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-25,20:16:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-30,20:01:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
VRTX,2023-09-05,19:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-07,20:30:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Business Wire,Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,13:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-15,13:24:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-19,13:57:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-21,20:16:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital
VRTX,2023-10-02,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,15:15:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-03,20:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 610 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-05,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Michel Lagarde to Its Bd of Directors
VRTX,2023-10-05,20:31:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-06,18:57:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-11,20:15:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-16,20:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,14:57:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,15:03:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA(R) (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:47:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) in Children With Cystic Fibrosis Ages 2 to 5 Years With at Least One F508del Mutation
VRTX,2023-10-17,19:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-17,19:15:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-18,20:18:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-19,20:14:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-19,20:19:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-26,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-26,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-31,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Business Wire,Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,20:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,16:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.97,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.97 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.08 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.04B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.04B >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -4-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -4-
VRTX,2023-11-06,21:01:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Leader Vertex Boosts Outlook After,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals (VRTX) reported third-quarter adjusted earnings of $4.08 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.65,revenues,up,Vertex said the revenue gains,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.7,earnings,up,Vertex raised its full-year guidance for,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital
VRTX,2023-11-08,21:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley
VRTX,2023-11-13,14:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Lab Design Tool Partners With Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Lab Design Tool Partners With Vertex Pharmaceuticals and LabOps Unite at Lab Asset & Facility Management (LAFM) 2023
VRTX,2023-11-13,20:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-14,17:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-15,15:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,15:33:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,21:17:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-16,06:45:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Business Wire,"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,06:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,21:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-17,21:17:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 19 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-17,21:26:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 35 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-19,08:35:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)"
VRTX,2023-11-20,16:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,DGAP News,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,Dow Jones Newswires,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,21:18:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in -2-
VRTX,2023-11-23,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:24:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-23,14:39:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-12-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX
VRTX,2023-12-08,16:16:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,16:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,17:04:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,18:26:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-09,12:47:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,Vertex Pharmaceuticals reported positive Phase 2 study results,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a Phase 2 study of VX-548,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement,NEWS-FLASH,Dow Jones Newswires,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement for Cas9
VRTX,2023-12-13,14:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,14:34:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,17:18:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,17:33:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,19:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,20:24:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,21:34:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital
VRTX,2023-12-15,17:54:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:23:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-18,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,94,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Business Wire,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,13:00:20,57CAAB,Vertex Pharmaceuticals Inc.,95,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,21:05:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
VRTX,2023-12-19,21:18:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-04,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-04,13:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
VRTX,2023-01-11,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex,PRESS-RELEASE,GlobeNewswire,"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase"
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by SVB Leerink
VRTX,2023-01-17,11:15:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $374.00/Share From $265.00 by SVB Leerink
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:00:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-17,13:08:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Hold by Canaccord Genuity
VRTX,2023-01-18,13:39:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $311.00/Share by Canaccord Genuity
VRTX,2023-01-18,19:54:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-01-19,17:20:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $296.00/Share From $293.00 by Piper Sandler
VRTX,2023-01-19,20:46:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Lee Registers 442 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-01-19,21:09:37,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 4,442 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-20,09:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2022 (VRTX)"
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-01-24,14:43:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $286.00/Share From $285.00 by Morgan Stanley
VRTX,2023-01-24,19:27:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 2,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,17:48:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-25,21:09:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 6,129 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:36:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-26,17:37:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:14:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-27,21:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 8,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,14:39:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 4,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-30,19:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Lee Registers 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,19:55:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Carney Registers 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:43:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Lee Sells 1,429 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-01-31,21:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Carney Sells 2,700 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,22:52:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-01,23:04:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-02,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 1,200 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-02,21:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 106 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 106 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-03,22:39:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 6,648 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-03,22:55:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Gifts 1,672 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.15,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.15 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.76,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.76 >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: Share Repurchase Program,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex completed enrollment in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -2-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -3-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -4-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year -5-
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $818.9M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $818.9M >VRTX
VRTX,2023-02-07,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.3B >VRTX
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2022 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $8.93 billion, an 18% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 819 $ 770,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income per share - diluted $ 3.15 $ 3.00,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex Pharmaceuticals Inc.: Acquired IPR&D in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Vertex Pharmaceuticals Inc.: On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex's CF product revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex Pharmaceuticals Inc.: our anticipated transaction with Entrada Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Filed an sNDA with the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,acquisitions-mergers,completed,"Vertex Pharmaceuticals Inc.: In September 2022, Vertex closed the acquisition of ViaCyte",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex is developing in partnership with CRISPR Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.28,products-services,,Vertex Pharmaceuticals Inc.: Consistent with its strategy to develop transformative medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 818.9 $ 770.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.19 $ 3.02 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,150.9 $ 13,432.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,,Vertex Pharmaceuticals Inc.: the company may repurchase stock,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2023-02-07,21:01:20,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2023-02-07,21:03:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals: Board of Directors Approved New Shr Repurchase Program, Authorizing Repurchase of Up to $3.0B of Common Stk, Program Does Not Have Expiration Date and Can Be Discontinued at Any Time >VRTX"
VRTX,2023-02-07,21:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals:: Full Yr 2023 Pdt Rev Guidance of $9.55B to $9.7B >VRTX
VRTX,2023-02-07,21:07:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3B Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3B Share Repurchase Program
VRTX,2023-02-07,21:13:36,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.76 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,21:22:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Sets $3 Billion Share Repurchase Program
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.44,earnings,up,Vertex earnings rocketed 25% to $3.76,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:04:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views -- IBD
VRTX,2023-02-07,22:12:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by SVB Leerink
VRTX,2023-02-08,10:01:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $365.00/Share From $374.00 by SVB Leerink
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-02-08,11:22:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $326.00/Share From $300.00 by HC Wainwright & Co.
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-02-08,13:11:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $342.00/Share From $313.00 by Barclays
VRTX,2023-02-08,14:33:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Piper Sandler
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-02-08,16:04:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $285.00/Share From $286.00 by Morgan Stanley
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,16:10:06,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Trikafta will gain FDA approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.59,equity-actions,up,Vertex projected higher-than-expected operating expenses for the year,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:11:51,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex's plans to begin enrolling patients,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat -- IBD
VRTX,2023-02-08,21:58:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,304 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,21:59:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:06:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,798 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:09:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 4,887 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:12:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 113 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:17:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 275 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 113 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:23:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 275 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-14,22:41:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:42:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,362 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,344 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:45:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 7,268 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-14,22:46:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 7,699 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,20:46:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-15,21:50:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-16,21:12:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:15:18,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 6,398 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:17:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,181 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-16,21:20:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 320 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 320 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-21,21:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7,PRESS-RELEASE,Business Wire,Vertex to Present at Cowen's 43(rd) Annual Health Care Conference on March 7
VRTX,2023-02-21,21:05:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7
VRTX,2023-02-22,19:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:48:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,19:49:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,21:29:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,002 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:33:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,402 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,21:53:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 480 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 480 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-22,22:03:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:06:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,359 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:12:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,498 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:16:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-22,22:18:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-23,20:54:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-24,21:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 2,401 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,12:38:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Biosciences announces collaboration with Vertex to,PRESS-RELEASE,PR Newswire,Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
VRTX,2023-02-28,21:30:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:31:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:47:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 4,238 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,21:56:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 5,034 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:00:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,22:01:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Sells 1,207 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,22:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-02-28,23:41:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:42:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,468 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:52:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 3,970 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-02-28,23:54:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 13,730 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-01,00:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,308 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance Of Investigational New Drug,NEWS-FLASH,Dow Jones Newswires,"Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-264, A Novel Encapsulated Cell Therapy For The Treatment Of Type 1 Diabetes >VRTX"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Business Wire,"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals To Initiate Phase 1/2 Clinical Trial in Coming Months >VRTX
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces FDA Clearance of Investigational New Drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex to initiate a Phase 1/2 clinical trial in the coming months,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-09,13:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The company previously received approval from Health Canada on the Clinical Trial Application (CTA),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes"
VRTX,2023-03-10,21:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,088 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-13,20:21:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,666 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-14,20:25:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 4,754 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Business Wire,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex to seek accelerated approval of VX-147,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Food and Drug Administration (FDA) recently granted inaxaplin Breakthrough Therapy Designation (BTD),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
VRTX,2023-03-16,21:12:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-17,17:09:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-20,20:27:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 2,746 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by Bernstein
VRTX,2023-03-21,10:03:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $344.00/Share by Bernstein
VRTX,2023-03-21,20:22:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 2,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-24,16:03:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals Inc.: our relationship with CRISPR Therapeutics with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Viacyte, Inc., which was acquired by Vertex in 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.18,acquisitions-mergers,,Crispr Therapeutics will not obtain any interest in Vertex,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
VRTX,2023-03-27,12:01:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and CRISPR Therapeutics Announce Licensing Agreement,NEWS-FLASH,Dow Jones Newswires,Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for Treatment of Type 1 Diabetes
VRTX,2023-03-28,20:17:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 1,768 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Argus Research
VRTX,2023-03-29,17:02:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $340.00 by Argus Research
VRTX,2023-04-03,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-03,12:00:45,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex and CRISPR Therapeutics entered into a strategic research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
VRTX,2023-04-04,20:45:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-04,21:19:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Surrenders 1,466 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-04,21:37:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Surrenders 176 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,20:25:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sanna Sells 522 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sanna Sells 522 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-04-06,21:27:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,labor-issues,,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M",NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals, Inc.: CEO, Pres Reshma Kewalraman 2022 Total Compensation $15.8M >VRTX"
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2023 Financial Results on May 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,12:05:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2023 Financial Results on May 1
VRTX,2023-04-10,14:16:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI,PRESS-RELEASE,Canadian News Wire,Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for ORKAMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Health Canada Market Authorization for ORKAMBI (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:16:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces Health Canada Market Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Health Canada Market Authorization for Orkambi in Children With Cystic Fibrosis Ages 1 to <2 Years
VRTX,2023-04-10,14:19:09,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Receives Health Canada Marketing Authorization for Orkambi Treatment in Pediatric Cystic Fibrosis >VRTX
VRTX,2023-04-10,14:46:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-10,15:01:28,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,Orkambi was previously approved by Health Canada for treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis
VRTX,2023-04-12,20:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-12,21:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:15:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 21,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-14,20:21:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 7,567 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-04-20,08:23:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2023 (VRTX)"
VRTX,2023-04-25,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Business Wire,Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-25,12:02:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the Bank of America Securities 2023 Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For TRIKAFTA(R),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations >VRTX
VRTX,2023-04-26,17:37:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval for TRIKAFTA(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
VRTX,2023-04-26,17:37:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Gets FDA OK of Trikafta,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA OK of Trikafta in Children 2-5 With Cystic Fibrosis With Certain Mutations >VRTX
VRTX,2023-04-26,18:03:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-26,18:18:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: FDA OKs Trikafta,FULL-ARTICLE,Dow Jones Newswires,Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations
VRTX,2023-04-27,20:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.69,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.69 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $3.05,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $3.05 >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $699.8M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $699.8M >VRTX
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -2-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -3-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2023 Financial -4-
VRTX,2023-05-01,20:01:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.37B >VRTX
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.37 billion, a 13% increase compared to Q1 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: CF product revenues Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex has also submitted an sNDA to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex Pharmaceuticals Inc.: The FDA granted Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,Vertex completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 Financial Results
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two additional Phase 3 studies of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The results from the Phase 2 study of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed enrollment and dosing in Part B of the Phase 1/2 study of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,start,Vertex plans to begin enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a 48-week Phase 2 study of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -2-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 794.0 $ 907.1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.72 $ 2.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 18,974.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -3-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,equity-actions,,"Vertex Pharmaceuticals Inc.: 3: ""Acquisition-related costs"" in the three months ended March 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2023 -4-
VRTX,2023-05-01,20:05:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY23 Rev $9.55B-$9.7B >VRTX
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.05 per share,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.1 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:15:42,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,unchanged,Vertex reiterated its guidance,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives -- IBD"
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:18:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:27:54,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 3,317 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.67,earnings,down,Vertex Pharmaceuticals on Monday said first-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-01,20:33:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex backed its guidance for the full year,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net Down On Higher Costs
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-05-02,09:51:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $384.00/Share From $342.00 by Barclays
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-05-02,10:27:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $326.00 by HC Wainwright & Co.
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
VRTX,2023-05-02,10:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $410.00/Share From $350.00 by Oppenheimer
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Neutral by Baird
VRTX,2023-05-02,10:57:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $325.00/Share From $280.00 by Baird
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2023-05-02,11:12:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $385.00/Share From $339.00 by Guggenheim
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-05-02,11:23:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $300.00 by Stifel
VRTX,2023-05-02,12:29:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.54,price-targets,upgrade,Vertex Pharmaceuticals stock price target raised to $456,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock price target raised to $456 from $341 at Truist
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-05-02,12:47:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $305.00/Share From $285.00 by Morgan Stanley
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-05-02,13:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $299.00 by RBC Capital
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2023-05-02,13:43:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $456.00/Share From $341.00 by Truist Securities
VRTX,2023-05-02,14:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-02,20:30:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 6,450 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-02,21:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 1,622 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-05-03,10:53:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $363.00/Share From $344.00 by Bernstein
VRTX,2023-05-03,20:39:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 4,508 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-03,20:46:19,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 580 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Announces U.S. FDA Approval For KALYDECO(R) (ivacaftor) To Treat Eligible Infants With CF Ages 1 Month And Older >VRTX
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Business Wire,Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:07:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces U.S. FDA Approval for KALYDECO(R) (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
VRTX,2023-05-03,21:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,781 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Piper Sandler at Overweight
VRTX,2023-05-04,10:24:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $385.00/Share by Piper Sandler
VRTX,2023-05-04,20:53:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 10,958 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-04,20:56:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sanna Sells 4,403 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-05,20:45:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Chmn Leiden Registers 879 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-05,21:15:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sanna Registers 422 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-05-08,19:15:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 1,125 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-08,20:06:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sanna Registers 2,850 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-09,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 2,004 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-05-30,10:10:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Initiated at Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Outperform by William Blair
VRTX,2023-05-30,12:02:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
VRTX,2023-05-30,14:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Coo Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,COO Arbuckle Registers 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:13:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 289 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 289 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-01,20:19:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Coo Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,COO Arbuckle Sells 82 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-06-08,14:04:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $323.00/Share From $315.00 by RBC Capital
VRTX,2023-06-08,23:29:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,products-services,,Vertex: FDA Granted Priority Review,NEWS-FLASH,Dow Jones Newswires,"Vertex: FDA Granted Priority Review for SCD and Standard Review for TDT and Assigned Prescription Drug User Fee Act Target Action Dates of Dec 8, 2023, and March 30, 2024, Respectively >VRTX"
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,95,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Business Wire,Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-09,15:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.0,earnings,,Vertex Pharmaceuticals Inc.: Abstract EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
VRTX,2023-06-15,20:33:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-20,20:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Presents Positive VX-880,PRESS-RELEASE,Business Wire,Vertex Presents Positive VX-880 Results From -2-
VRTX,2023-06-23,22:55:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Business Wire,Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex's first clinical program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
VRTX,2023-06-26,11:33:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Pharmaceuticals and Lonza Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Vertex Pharmaceuticals and Lonza Collaboration to Support the Manufacture of Vertex's Portfolio of Investigational Stem Cell-Derived, Fully Differentiated Insulin-Producing Islet Cell Therapies for People With T1D >VRTX"
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2023-06-26,15:56:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $375.00 by Evercore ISI Group
VRTX,2023-06-29,14:09:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Trading Halt - VRTX,PRESS-RELEASE,Canadian News Wire,Canadian Investment Regulatory Organization Trading Halt - VRTX
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2023 Financial Results on August 1,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,12:01:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2023 Financial Results on August 1
VRTX,2023-06-30,13:20:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-03,12:44:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $340.00/Share From $305.00 by Morgan Stanley
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Business Wire,European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves ORKAMBI(R) (lumacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
VRTX,2023-07-05,07:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R),NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: European Commission Approves ORKAMBI(R) (lumacaftor/ivacaftor) for Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old >VRTX
VRTX,2023-07-17,16:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-17,17:45:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 7,828 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-18,20:18:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2023-07-21,17:03:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $400.00/Share From $350.00 by B of A Securities
VRTX,2023-07-21,19:24:43,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-07-21,21:30:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.65,revenues,up,Vertex Pharmaceuticals Inc.: the company's overall sales rise from,FULL-ARTICLE,Dow Jones Newswires,"Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst -- Barrons.com"
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.52 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $3.89,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $3.89 >VRTX
VRTX,2023-08-01,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $915.7M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $915.7M >VRTX
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -2-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -3-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -4-
VRTX,2023-08-01,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2023 Financial -5-
VRTX,2023-08-01,20:01:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.49B >VRTX
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.49 billion, a 14% increase compared to Q2 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the second quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.51,products-services,complete,"Vertex Pharmaceuticals Inc.: More recently, Vertex also completed enrollment",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 Financial Results
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Fda has granted Fast Track designation to VX-522,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Two global Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Inaxaplin was granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.39,products-services,,Vertex and Lonza announced a strategic agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -2-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 3.55 $ 3.17 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -3-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP net income $ 915.7 $ 810.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,014.0 $ 930.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 20,349.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -4-
VRTX,2023-08-01,20:01:40,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2023 -5-
VRTX,2023-08-01,20:01:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raises 2023 View To Rev $9.7B-$9.8B >VRTX
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.0,revenues,,Vertex Pharmaceuticals Inc.: the company reported nearly $2.2 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:15:36,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,"Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower -- IBD"
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:18:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals 2Q Profit Up On,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,20:33:35,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex also lifted full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-01,21:15:58,57CAAB,Vertex Pharmaceuticals Inc.,98,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise -- IBD
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-08-02,10:56:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $399.00/Share From $384.00 by Barclays
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Bernstein
VRTX,2023-08-02,11:07:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by Bernstein
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2023-08-02,13:04:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $425.00/Share From $410.00 by Wells Fargo
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-08-02,13:28:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $389.00/Share From $385.00 by BMO Capital
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,14:08:17,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-08-02,15:21:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $352.00/Share From $340.00 by Morgan Stanley
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-08-02,16:08:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $343.00/Share From $325.00 by RBC Capital
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,16:25:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration is also considering approving Vertex's gene-editing drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Trikafta sales climbed 18%,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex also earned $3.89 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-02,20:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.72,revenues,up,Vertex raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News -- IBD
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2023-08-07,11:37:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $315.00/Share From $312.00 by Canaccord Genuity
VRTX,2023-08-09,14:18:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-09,16:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-10,14:54:43,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:09:40,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Sachdev Registers 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-10,17:54:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Kearney Registers 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-11,20:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 63 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 63 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-11,20:06:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-08-14,20:06:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Sells 10,031 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 5,750 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-14,20:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Kearney Sells 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-19,07:23:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2023 (VRTX)"
VRTX,2023-08-23,16:39:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-25,20:16:24,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 2,500 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-08-30,20:01:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,marketing,,Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
VRTX,2023-09-05,19:06:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-07,20:30:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Business Wire,Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-14,13:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Researchers Awarded 2024 Breakthrough Prize,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,products-services,positive,Kaftrio has demonstrated unprecedented clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,12:52:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for KAFTRIO,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-09-15,13:09:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-15,13:24:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets European Regulators' Nod for Cystic Fibrosis Drug
VRTX,2023-09-19,13:57:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-21,20:16:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-09-29,11:40:17,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $348.00/Share From $343.00 by RBC Capital
VRTX,2023-10-02,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,15:15:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-03,20:09:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 610 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Biller Sells 610 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study",PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-03,23:47:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,"Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting"
VRTX,2023-10-05,12:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Michel Lagarde to its Board of Directors
VRTX,2023-10-05,12:00:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Michel Lagarde to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Vertex Appoints Michel Lagarde to Its Bd of Directors
VRTX,2023-10-05,20:31:41,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-06,18:57:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-10-09,13:14:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $359.00/Share From $352.00 by Morgan Stanley
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:00:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2023 Financial Results on November 6,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-10,12:08:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2023 Financial Results on November 6
VRTX,2023-10-11,20:15:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 242 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-16,20:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,14:57:30,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-17,15:03:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA,PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:44:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for TRIKAFTA(R) (elexacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
VRTX,2023-10-17,18:47:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor),NEWS-FLASH,Dow Jones Newswires,Vertex Pharma: Health Canada Grants Market Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) in Children With Cystic Fibrosis Ages 2 to 5 Years With at Least One F508del Mutation
VRTX,2023-10-17,19:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-17,19:15:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Gets Health Canada Label Expansion Approval for Cystic Fibrosis Treatment
VRTX,2023-10-18,20:18:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 12,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-19,20:14:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 243 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-10-19,20:19:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-10-26,12:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-26,12:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at Upcoming Investor Conferences
VRTX,2023-10-31,15:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-02,12:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Business Wire,Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: This interim analysis through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA(R) at the North American Cystic Fibrosis Conference
VRTX,2023-11-02,20:09:22,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,651 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,16:54:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Dir Sachs Registers 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q EPS $3.97,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q EPS $3.97 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Adj EPS $4.08 >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 3Q Net $1.04B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Net $1.04B >VRTX
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -2-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -3-
VRTX,2023-11-06,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Third Quarter 2023 Financial -4-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Third Quarter 2023 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.63,revenues,up,"Vertex Pharmaceuticals Inc.: Product revenue of $2.48 billion, a 6% increase compared to Q3 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,Vertex Pharmaceuticals Inc.: Net product revenue in the third quarter of 2023 increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex is also reiterating its guidance for full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada granted market authorization for the use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: Clinical data from,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 Financial Results
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate another Phase 2 study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Clinical trial to evaluate the safety and efficacy of VX-880,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.52,products-services,,Vertex has discontinued development of VX-864,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -2-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,063.6 $1,039.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 4.01 $ 3.63 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,94,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 21,726.2 $ 18,150.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -3-
VRTX,2023-11-06,21:01:21,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Third Quarter 2023 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Third Quarter 2023 -4-
VRTX,2023-11-06,21:01:28,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Rev $2.48B >VRTX
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:16:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,earnings,up,Leader Vertex Boosts Outlook After,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:22:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals reported adjusted earnings of $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,IBD Tech Leader Vertex Boosts Outlook After Strong Earnings -- IBD
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals' profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-06,21:31:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,"Vertex said revenue growth, higher",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.61,earnings,positive,Vertex Pharmaceuticals (VRTX) reported third-quarter adjusted earnings of $4.08 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.65,revenues,up,Vertex said the revenue gains,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,09:37:43,57CAAB,Vertex Pharmaceuticals Inc.,93,0.7,earnings,up,Vertex raised its full-year guidance for,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Alteryx, Tripadvisor, Vertex, UBS, RingCentral, Sanmina, Uber, and More -- Barrons.com"
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-11-07,13:25:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $390.00/Share From $380.00 by HC Wainwright & Co.
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2023-11-07,15:24:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $373.00/Share From $340.00 by Stifel
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2023-11-07,17:01:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $380.00/Share From $370.00 by Cantor Fitzgerald
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2023-11-07,17:35:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $389.00 by BMO Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-11-07,18:33:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $347.00/Share From $350.00 by RBC Capital
VRTX,2023-11-08,21:12:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Sells 11,250 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2023-11-08,21:56:27,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $364.00/Share From $359.00 by Morgan Stanley
VRTX,2023-11-13,14:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Lab Design Tool Partners With Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Lab Design Tool Partners With Vertex Pharmaceuticals and LabOps Unite at Lab Asset & Facility Management (LAFM) 2023
VRTX,2023-11-13,20:54:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-14,17:06:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Bozic Registers 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-15,15:30:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Sachdev Registers 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,15:33:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-15,21:17:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,097 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-16,06:45:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Business Wire,"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,06:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia"
VRTX,2023-11-16,21:17:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Sells 5,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-17,21:17:03,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 19 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 19 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-17,21:26:21,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Sachdev Sells 35 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Sachdev Sells 35 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2023-11-19,08:35:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 3Q 2023 (VRTX)"
VRTX,2023-11-20,16:57:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,DGAP News,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,13:50:18,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Vertex and Wintermute,PRESS-RELEASE,Dow Jones Newswires,Bitget Expands Ecosystem with the listing of Vertex (VRTX) Token
VRTX,2023-11-21,21:18:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in,PRESS-RELEASE,Business Wire,European Commission Approves KAFTRIO(R) in -2-
VRTX,2023-11-23,14:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission Approves KAFTRIO(R) in Combination With Ivacaftor,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Approves KAFTRIO(R) in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
VRTX,2023-11-23,14:24:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-23,14:39:47,57CAAB,Vertex Pharmaceuticals Inc.,92,0.57,products-services,granted,European Commission has granted approval for the label expansion of Kaftrio,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.84,products-services,positive,Vertex Pharmaceuticals Inc.: It is encouraging to see such positive clinical trial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-24,14:13:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO(R) in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Canadian News Wire,Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Grants Market Authorization for KALYDECO (ivacaftor),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
VRTX,2023-11-29,19:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: Health Canada Has Granted Market Authorization for the Expanded Use of Kalydeco
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:25:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,products-services,,Vertex Pharmaceuticals' Kalydeco Gets Expanded,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-11-29,19:40:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kalydeco was previously approved by Health Canada,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada
VRTX,2023-12-05,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Business Wire,Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Appoints Nancy Thornberry to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Appoints Nancy Thornberry to its Board of Directors
VRTX,2023-12-05,21:01:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.47,labor-issues,,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Appoints Nancy Thornberry to Board as Independent Director >VRTX
VRTX,2023-12-08,16:16:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,16:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Get FDA OK of Casgevy Gene Therapy,FULL-ARTICLE,Dow Jones Newswires,"CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease"
VRTX,2023-12-08,17:04:06,57CAAB,Vertex Pharmaceuticals Inc.,93,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Business Wire,Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,17:52:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex has submitted a BLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
VRTX,2023-12-08,18:26:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-09,12:47:45,57CAAB,Vertex Pharmaceuticals Inc.,95,0.57,products-services,granted,Vertex Pharmaceuticals Inc. (VRTX) on Friday got U.S. regulatory approval for a sickle-cell disease treatment,FULL-ARTICLE,MarketWatch,"MW Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment"
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2023-12-11,12:35:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $397.00/Share From $390.00 by HC Wainwright & Co.
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
VRTX,2023-12-11,13:59:19,57CAAB,Vertex Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $415.00/Share From $408.00 by Barclays
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: our Phase 3 studies of VX-548,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,11:30:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Vertex Announces Positive Results From Phase 2 Study of VX-548,NEWS-FLASH,Dow Jones Newswires,Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,Vertex Pharmaceuticals reported positive Phase 2 study results,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,13:46:35,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated a Phase 2 study of VX-548,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative -- IBD
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
VRTX,2023-12-13,14:00:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement,NEWS-FLASH,Dow Jones Newswires,Editas Medicine and Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement for Cas9
VRTX,2023-12-13,14:19:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,14:34:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
VRTX,2023-12-13,17:18:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,17:33:37,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
VRTX,2023-12-13,19:51:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Coo Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"COO Arbuckle Registers 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,20:24:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-13,21:34:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"Chmn Leiden Registers 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2023-12-14,15:46:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $379.00/Share From $347.00 by RBC Capital
VRTX,2023-12-15,17:54:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CEO Kewalramani Registers 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:23:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Coo Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Sells 8,603 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 5,098 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-15,21:39:53,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Sells 13,354 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2023-12-18,13:00:02,57CAAB,Vertex Pharmaceuticals Inc.,94,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Business Wire,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,13:00:20,57CAAB,Vertex Pharmaceuticals Inc.,95,0.49,partnerships,,Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
VRTX,2023-12-18,21:05:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
VRTX,2023-12-19,21:18:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Sells 17,135 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:03:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals >VRTX
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Zai Lab Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Zai Lab and Vertex Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,NEWS-FLASH,Dow Jones Newswires,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler
VRTX,2025-01-30,11:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo
VRTX,2025-01-31,00:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,00:19:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Business Wire,Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,09:35:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment.,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Vertex's oral non-opioid,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,10:04:13,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,10:26:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval -- WSJ
VRTX,2025-01-31,10:33:22,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,11:26:46,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,11:49:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,12:25:44,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,12:39:18,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Walgreens, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank
VRTX,2025-01-31,15:57:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex is also testing the drug as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller -- Barrons.com
VRTX,2025-01-31,17:38:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,19:51:17,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,21:17:51,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.50,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.98,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $913M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $913M >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -5-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2025-02-10,21:01:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX
VRTX,2025-02-10,21:02:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the ""Company"") announced the retirement of Stuart A. Arbuckle, the Company's Executive Vice President and Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,labor-issues,,"Vertex Pharmaceuticals Inc.: The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: the Company's Annual Report on Form 10-K for the year ended December 31, 2024",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:11:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley
VRTX,2025-02-11,14:21:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays
VRTX,2025-02-11,14:51:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank
VRTX,2025-02-11,16:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-11,17:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities
VRTX,2025-02-11,21:12:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity
VRTX,2025-02-12,21:25:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:28:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:36:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:40:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 3,433 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 310 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-12,21:59:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:01:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-14,21:41:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:30:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,08:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-19,21:26:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 671 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 671 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,21:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,657 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,21:38:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 244 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,22:04:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-20,08:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital
VRTX,2025-02-20,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-24,21:08:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:01:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-25,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 848 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 884 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 884 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:11:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:13:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:16:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:17:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:26:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,15:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-27,15:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,16:24:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations >VRTX
VRTX,2025-02-28,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:38:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:43:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 530 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-28,22:13:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-03,21:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-04,18:42:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-05,21:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-06,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-10,16:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,17:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,18:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,20:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod,PRESS-RELEASE,GlobeNewswire,CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
VRTX,2025-03-10,20:05:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod,NEWS-FLASH,Dow Jones Newswires,CervoMed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
VRTX,2025-03-12,20:08:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:11:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-13,15:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-17,20:09:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-28,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Business Wire,Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:49:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-28,21:04:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital
VRTX,2025-04-07,16:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: European Commission Approves Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex: European Commission Approves Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis >VRTX
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-11,09:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Business Wire,"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-11,09:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,legal,,Toolgen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom,PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,"In December 2023, Vertex entered into a licensing agreement with Editas Medicine",PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald
VRTX,2025-04-28,11:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib,PRESS-RELEASE,GlobeNewswire,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi(R)) in Patients with Myelofibrosis
VRTX,2025-05-02,13:48:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.06,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $646.3M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $646.3M >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -5-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -5-
VRTX,2025-05-05,20:03:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX
VRTX,2025-05-05,20:15:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:45:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-05,21:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink Partners
VRTX,2025-05-06,13:23:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald
VRTX,2025-05-06,13:49:37,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Neurocrine, and More -- Barrons.com"
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan
VRTX,2025-05-06,14:31:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-06,15:17:48,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Constellation Energy, and More -- Barrons.com"
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital
VRTX,2025-05-06,16:31:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Cantor Fitzgerald each maintained Overweight ratings for Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com
VRTX,2025-05-06,16:52:29,57CAAB,Vertex Pharmaceuticals Inc.,92,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Tesla, Ford, Constellation Energy, SolarEdge, Vertex, Hims & Hers, DoorDash, and More -- Barrons.com"
VRTX,2025-05-06,20:40:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-15,14:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-15,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-15,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)"
VRTX,2025-05-19,20:24:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Vertex Pharmaceuticals Inc.: the Company is authorized to repurchase up to $4.775 billion,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2025-05-19,20:40:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Authorizes Additional Buyback,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Authorizes Additional Buyback of Up to $4B
VRTX,2025-05-19,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 52 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley
VRTX,2025-06-20,23:15:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Business Wire,Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-20,23:15:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Ono Pharmaceutical and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Ono and Vertex have entered into an exclusive collaboration,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,11:44:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-02,20:41:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Canadian News Wire,"Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-08-04,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.99,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $4.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $1.03B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $1.03B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -5-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -5-
VRTX,2025-08-04,20:06:34,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the Company announced the retirement of David Altshuler, Executive Vice President and Chief",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-08-04,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX
VRTX,2025-08-04,20:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX
VRTX,2025-08-04,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex: Announces Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Results From Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported adjusted earnings of $4.52 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,21:06:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,23:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,00:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.78,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities
VRTX,2025-08-05,20:20:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat -- IBD
VRTX,2025-08-06,12:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo
VRTX,2025-08-06,12:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity
VRTX,2025-08-07,20:20:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-07,20:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)"
VRTX,2025-08-27,13:42:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-08-29,20:02:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-09-02,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Business Wire,Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
VRTX,2025-09-03,17:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Business Wire,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.68,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group
VRTX,2025-09-23,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Partners with Basketball World Champion Jayson Tatum to,PRESS-RELEASE,Business Wire,"Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX(R), a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain"
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink Partners
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink Partners
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:46:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept on IgA Nephropathy >VRTX
VRTX,2025-09-25,12:10:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-09-25,12:25:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-10-02,14:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup
VRTX,2025-10-03,20:13:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 694 Of Vertex Pharmaceuticals Inc,FULL-ARTICLE,Dow Jones Newswires,VP Biller Sells 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals: To Submit First BLA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: To Submit First BLA Module Before End of Year >VRTX
VRTX,2025-10-17,13:06:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2b/3 Povetacicept Study,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2b/3 Povetacicept Study in Primary Membranous Nephropathy >VRTX
VRTX,2025-10-17,14:04:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-17,14:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-27,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Business Wire,Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-27,20:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-31,05:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,above-expectations,Vertex Pharmaceuticals Inc.: the company has delivered better-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma's Stock Has Tumbled. Earnings Will Stop the Pain. -- Barrons.com
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:03:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals >VRTX
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Zai Lab Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Zai Lab and Vertex Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,NEWS-FLASH,Dow Jones Newswires,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler
VRTX,2025-01-30,11:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo
VRTX,2025-01-31,00:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,00:19:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Business Wire,Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,09:35:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment.,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Vertex's oral non-opioid,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,10:04:13,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,10:26:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval -- WSJ
VRTX,2025-01-31,10:33:22,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,11:26:46,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,11:49:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,12:25:44,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,12:39:18,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Walgreens, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank
VRTX,2025-01-31,15:57:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex is also testing the drug as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller -- Barrons.com
VRTX,2025-01-31,17:38:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,19:51:17,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,21:17:51,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.50,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.98,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $913M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $913M >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -5-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2025-02-10,21:01:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX
VRTX,2025-02-10,21:02:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the ""Company"") announced the retirement of Stuart A. Arbuckle, the Company's Executive Vice President and Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,labor-issues,,"Vertex Pharmaceuticals Inc.: The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: the Company's Annual Report on Form 10-K for the year ended December 31, 2024",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:11:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley
VRTX,2025-02-11,14:21:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays
VRTX,2025-02-11,14:51:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank
VRTX,2025-02-11,16:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-11,17:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities
VRTX,2025-02-11,21:12:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity
VRTX,2025-02-12,21:25:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:28:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:36:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:40:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 3,433 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 310 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-12,21:59:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:01:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-14,21:41:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:30:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,08:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-19,21:26:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 671 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 671 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,21:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,657 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,21:38:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 244 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,22:04:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-20,08:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital
VRTX,2025-02-20,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-24,21:08:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:01:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-25,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 848 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 884 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 884 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:11:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:13:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:16:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:17:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:26:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,15:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-27,15:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,16:24:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations >VRTX
VRTX,2025-02-28,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:38:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:43:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 530 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-28,22:13:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-03,21:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-04,18:42:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-05,21:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-06,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-10,16:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,17:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,18:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,20:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod,PRESS-RELEASE,GlobeNewswire,CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
VRTX,2025-03-10,20:05:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod,NEWS-FLASH,Dow Jones Newswires,CervoMed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
VRTX,2025-03-12,20:08:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:11:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-13,15:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-17,20:09:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-28,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Business Wire,Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:49:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-28,21:04:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital
VRTX,2025-04-07,16:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: European Commission Approves Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex: European Commission Approves Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis >VRTX
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-11,09:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Business Wire,"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-11,09:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,legal,,Toolgen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom,PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,"In December 2023, Vertex entered into a licensing agreement with Editas Medicine",PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald
VRTX,2025-04-28,11:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib,PRESS-RELEASE,GlobeNewswire,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi(R)) in Patients with Myelofibrosis
VRTX,2025-05-02,13:48:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.06,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $646.3M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $646.3M >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -5-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -5-
VRTX,2025-05-05,20:03:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX
VRTX,2025-05-05,20:15:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:45:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-05,21:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink Partners
VRTX,2025-05-06,13:23:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald
VRTX,2025-05-06,13:49:37,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Neurocrine, and More -- Barrons.com"
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan
VRTX,2025-05-06,14:31:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-06,15:17:48,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Constellation Energy, and More -- Barrons.com"
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital
VRTX,2025-05-06,16:31:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Cantor Fitzgerald each maintained Overweight ratings for Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com
VRTX,2025-05-06,16:52:29,57CAAB,Vertex Pharmaceuticals Inc.,92,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Tesla, Ford, Constellation Energy, SolarEdge, Vertex, Hims & Hers, DoorDash, and More -- Barrons.com"
VRTX,2025-05-06,20:40:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-15,14:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-15,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-15,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)"
VRTX,2025-05-19,20:24:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Vertex Pharmaceuticals Inc.: the Company is authorized to repurchase up to $4.775 billion,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2025-05-19,20:40:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Authorizes Additional Buyback,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Authorizes Additional Buyback of Up to $4B
VRTX,2025-05-19,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 52 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley
VRTX,2025-06-20,23:15:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Business Wire,Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-20,23:15:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Ono Pharmaceutical and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Ono and Vertex have entered into an exclusive collaboration,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,11:44:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-02,20:41:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Canadian News Wire,"Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-08-04,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.99,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $4.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $1.03B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $1.03B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -5-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -5-
VRTX,2025-08-04,20:06:34,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the Company announced the retirement of David Altshuler, Executive Vice President and Chief",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-08-04,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX
VRTX,2025-08-04,20:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX
VRTX,2025-08-04,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex: Announces Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Results From Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported adjusted earnings of $4.52 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,21:06:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,23:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,00:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.78,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities
VRTX,2025-08-05,20:20:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat -- IBD
VRTX,2025-08-06,12:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo
VRTX,2025-08-06,12:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity
VRTX,2025-08-07,20:20:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-07,20:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)"
VRTX,2025-08-27,13:42:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-08-29,20:02:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-09-02,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Business Wire,Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
VRTX,2025-09-03,17:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Business Wire,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.68,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group
VRTX,2025-09-23,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Partners with Basketball World Champion Jayson Tatum to,PRESS-RELEASE,Business Wire,"Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX(R), a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain"
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink Partners
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink Partners
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:46:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept on IgA Nephropathy >VRTX
VRTX,2025-09-25,12:10:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-09-25,12:25:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-10-02,14:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup
VRTX,2025-10-03,20:13:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 694 Of Vertex Pharmaceuticals Inc,FULL-ARTICLE,Dow Jones Newswires,VP Biller Sells 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals: To Submit First BLA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: To Submit First BLA Module Before End of Year >VRTX
VRTX,2025-10-17,13:06:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2b/3 Povetacicept Study,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2b/3 Povetacicept Study in Primary Membranous Nephropathy >VRTX
VRTX,2025-10-17,14:04:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-17,14:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-27,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Business Wire,Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-27,20:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-31,05:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,above-expectations,Vertex Pharmaceuticals Inc.: the company has delivered better-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma's Stock Has Tumbled. Earnings Will Stop the Pain. -- Barrons.com
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:03:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals >VRTX
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Zai Lab Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Zai Lab and Vertex Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,NEWS-FLASH,Dow Jones Newswires,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler
VRTX,2025-01-30,11:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo
VRTX,2025-01-31,00:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,00:19:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Business Wire,Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,09:35:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment.,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Vertex's oral non-opioid,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,10:04:13,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,10:26:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval -- WSJ
VRTX,2025-01-31,10:33:22,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,11:26:46,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,11:49:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,12:25:44,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,12:39:18,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Walgreens, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank
VRTX,2025-01-31,15:57:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex is also testing the drug as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller -- Barrons.com
VRTX,2025-01-31,17:38:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,19:51:17,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,21:17:51,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.50,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.98,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $913M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $913M >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -5-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2025-02-10,21:01:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX
VRTX,2025-02-10,21:02:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the ""Company"") announced the retirement of Stuart A. Arbuckle, the Company's Executive Vice President and Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,labor-issues,,"Vertex Pharmaceuticals Inc.: The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: the Company's Annual Report on Form 10-K for the year ended December 31, 2024",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:11:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley
VRTX,2025-02-11,14:21:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays
VRTX,2025-02-11,14:51:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank
VRTX,2025-02-11,16:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-11,17:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities
VRTX,2025-02-11,21:12:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity
VRTX,2025-02-12,21:25:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:28:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:36:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:40:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 3,433 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 310 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-12,21:59:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:01:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-14,21:41:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:30:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,08:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-19,21:26:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 671 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 671 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,21:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,657 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,21:38:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 244 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,22:04:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-20,08:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital
VRTX,2025-02-20,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-24,21:08:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:01:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-25,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 848 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 884 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 884 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:11:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:13:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:16:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:17:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:26:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,15:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-27,15:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,16:24:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations >VRTX
VRTX,2025-02-28,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:38:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:43:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 530 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-28,22:13:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-03,21:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-04,18:42:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-05,21:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-06,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-10,16:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,17:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,18:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,20:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod,PRESS-RELEASE,GlobeNewswire,CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
VRTX,2025-03-10,20:05:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod,NEWS-FLASH,Dow Jones Newswires,CervoMed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
VRTX,2025-03-12,20:08:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:11:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-13,15:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-17,20:09:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-28,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Business Wire,Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:49:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-28,21:04:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital
VRTX,2025-04-07,16:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: European Commission Approves Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex: European Commission Approves Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis >VRTX
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-11,09:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Business Wire,"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-11,09:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,legal,,Toolgen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom,PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,"In December 2023, Vertex entered into a licensing agreement with Editas Medicine",PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald
VRTX,2025-04-28,11:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib,PRESS-RELEASE,GlobeNewswire,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi(R)) in Patients with Myelofibrosis
VRTX,2025-05-02,13:48:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.06,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $646.3M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $646.3M >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -5-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -5-
VRTX,2025-05-05,20:03:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX
VRTX,2025-05-05,20:15:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:45:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-05,21:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink Partners
VRTX,2025-05-06,13:23:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald
VRTX,2025-05-06,13:49:37,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Neurocrine, and More -- Barrons.com"
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan
VRTX,2025-05-06,14:31:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-06,15:17:48,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Constellation Energy, and More -- Barrons.com"
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital
VRTX,2025-05-06,16:31:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Cantor Fitzgerald each maintained Overweight ratings for Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com
VRTX,2025-05-06,16:52:29,57CAAB,Vertex Pharmaceuticals Inc.,92,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Tesla, Ford, Constellation Energy, SolarEdge, Vertex, Hims & Hers, DoorDash, and More -- Barrons.com"
VRTX,2025-05-06,20:40:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-15,14:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-15,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-15,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)"
VRTX,2025-05-19,20:24:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Vertex Pharmaceuticals Inc.: the Company is authorized to repurchase up to $4.775 billion,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2025-05-19,20:40:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Authorizes Additional Buyback,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Authorizes Additional Buyback of Up to $4B
VRTX,2025-05-19,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 52 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley
VRTX,2025-06-20,23:15:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Business Wire,Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-20,23:15:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Ono Pharmaceutical and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Ono and Vertex have entered into an exclusive collaboration,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,11:44:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-02,20:41:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Canadian News Wire,"Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-08-04,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.99,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $4.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $1.03B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $1.03B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -5-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -5-
VRTX,2025-08-04,20:06:34,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the Company announced the retirement of David Altshuler, Executive Vice President and Chief",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-08-04,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX
VRTX,2025-08-04,20:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX
VRTX,2025-08-04,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex: Announces Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Results From Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported adjusted earnings of $4.52 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,21:06:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,23:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,00:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.78,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities
VRTX,2025-08-05,20:20:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat -- IBD
VRTX,2025-08-06,12:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo
VRTX,2025-08-06,12:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity
VRTX,2025-08-07,20:20:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-07,20:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)"
VRTX,2025-08-27,13:42:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-08-29,20:02:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-09-02,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Business Wire,Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
VRTX,2025-09-03,17:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Business Wire,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.68,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group
VRTX,2025-09-23,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Partners with Basketball World Champion Jayson Tatum to,PRESS-RELEASE,Business Wire,"Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX(R), a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain"
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink Partners
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink Partners
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:46:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept on IgA Nephropathy >VRTX
VRTX,2025-09-25,12:10:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-09-25,12:25:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-10-02,14:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup
VRTX,2025-10-03,20:13:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 694 Of Vertex Pharmaceuticals Inc,FULL-ARTICLE,Dow Jones Newswires,VP Biller Sells 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals: To Submit First BLA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: To Submit First BLA Module Before End of Year >VRTX
VRTX,2025-10-17,13:06:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2b/3 Povetacicept Study,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2b/3 Povetacicept Study in Primary Membranous Nephropathy >VRTX
VRTX,2025-10-17,14:04:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-17,14:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-27,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Business Wire,Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-27,20:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-31,05:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,above-expectations,Vertex Pharmaceuticals Inc.: the company has delivered better-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma's Stock Has Tumbled. Earnings Will Stop the Pain. -- Barrons.com
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:00:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
VRTX,2025-01-07,12:03:06,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals >VRTX
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Zai Lab Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,This collaboration with Vertex to,PRESS-RELEASE,Business Wire,"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore"
VRTX,2025-01-10,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Zai Lab and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Zai Lab and Vertex Announce Strategic Agreement -2-
VRTX,2025-01-10,12:30:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Zai Lab Announce Strategic Agreement,NEWS-FLASH,Dow Jones Newswires,"Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore"
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
VRTX,2025-01-10,14:23:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $555.00 by Wells Fargo
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Business Wire,Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Tezacaftor/deutivacaftor) approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"On December 31, 2024, Vertex received regulatory approval for CASGEVY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex has entered into an exclusive collaboration and license agreement with Zai Lab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-12,22:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex initiated the Phase 3 portion of the Phase 1/2/3 study of zimislecel in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,12:30:10,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
VRTX,2025-01-27,15:08:39,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $533.00/Share From $535.00 by Piper Sandler
VRTX,2025-01-30,11:06:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo
VRTX,2025-01-31,00:04:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,00:19:54,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: the company's oral non-opioid pain medication, received Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
VRTX,2025-01-31,07:00:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Business Wire,Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,07:00:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: The Conditional Marketing Authorization in Great Britain for CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces CASGEVY(R) Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
VRTX,2025-01-31,09:35:15,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment.,FULL-ARTICLE,MarketWatch,MW Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,09:59:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Vertex's oral non-opioid,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ"
VRTX,2025-01-31,10:04:13,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,10:26:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Vertex Stock Rises After Non-Opioid Painkiller Gets FDA Approval -- WSJ
VRTX,2025-01-31,10:33:22,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More -- Barrons.com"
VRTX,2025-01-31,11:26:46,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,11:49:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More -- Barrons.com"
VRTX,2025-01-31,12:25:44,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,12:39:18,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Walgreens, Visa, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-01-31,13:39:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $550.00/Share From $535.00 by HC Wainwright & Co.
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-01-31,15:04:38,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $433.00/Share From $430.00 by Scotiabank
VRTX,2025-01-31,15:57:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex is also testing the drug as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller -- Barrons.com
VRTX,2025-01-31,17:38:54,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,19:51:17,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-01-31,21:17:51,57CAAB,Vertex Pharmaceuticals Inc.,92,0.5,products-services,granted,Vertex Pharmaceuticals Inc.: the Food and Drug Administration approved the company's non-opioid pain treatment,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More -- Barrons.com"
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q EPS $3.50,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Adj EPS $3.98,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 4Q Net $913M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Net $913M >VRTX
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -2-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -3-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Fourth Quarter and Full Year 2024 -5-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Fourth Quarter 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2024 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Full year product revenue of $11.02 billion, a 12% increase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the launch of our fifth CF medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,products-services,,Vertex Pharmaceuticals Inc.: the continuing global launch of CASGEVY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,equity-actions,,Vertex Pharmaceuticals Inc.: Combined GAAP and Non-GAAP R&D and SG&A expenses were $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,equity-actions,up,Vertex Pharmaceuticals Inc.: Acquired IPR&D (AIPR&D) expenses were $88 million compared to $18 million in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and Non-GAAP net income were $913 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.82,equity-actions,up,Vertex Pharmaceuticals Inc.: AIPR&D expenses were $4.6 billion compared to $527 million in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Vertex's acquisition of Alpine Immune Sciences during 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex's total revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Inc.: Total revenue $11.75 to $12.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex received FDA approval for the expanded use of TRIKAFTA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,"In December 2024, Vertex announced results of the Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,Vertex plans to initiate a Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex has initiated AMPLIFIED, a Phase 2 proof-of-concept study of inaxaplin",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The global Phase 3 RAINIER study of povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The clinical trial for VX-264,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -2-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.49,partnerships,,Vertex Pharmaceuticals Inc.: A strategic collaboration with Orna Therapeutics for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -3-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $1,036.3 $1,096.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,533.2 $ 22,730.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -4-
VRTX,2025-02-10,21:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Fourth Quarter and -5-
VRTX,2025-02-10,21:01:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX
VRTX,2025-02-10,21:02:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the ""Company"") announced the retirement of Stuart A. Arbuckle, the Company's Executive Vice President and Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,labor-issues,,"Vertex Pharmaceuticals Inc.: The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:08:50,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,"Vertex Pharmaceuticals Inc.: the Company's Annual Report on Form 10-K for the year ended December 31, 2024",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-02-10,21:11:44,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,21:56:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals Posts Higher 4Q Revenue,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported earnings of $3.98 a share,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-10,22:11:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,"For the full year, Vertex guided for revenue between $11.75 billion",FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Posts Higher 4Q Revenue
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-02-11,12:41:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $459.00/Share From $450.00 by Morgan Stanley
VRTX,2025-02-11,14:21:09,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
VRTX,2025-02-11,14:50:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $467.00/Share From $435.00 by Barclays
VRTX,2025-02-11,14:51:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-02-11,15:05:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $450.00/Share From $433.00 by Scotiabank
VRTX,2025-02-11,16:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-11,17:00:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-11,17:27:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $407.00/Share From $402.00 by RBC Capital
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-02-11,17:47:53,57CAAB,Vertex Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $520.00/Share From $460.00 by Truist Securities
VRTX,2025-02-11,21:12:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex expects $11.75 billion to $12 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity
VRTX,2025-02-12,13:33:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $424.00/Share From $408.00 by Canaccord Genuity
VRTX,2025-02-12,21:25:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Ambrose Sells 1,376 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:28:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:31:02,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Atkinson III Sells 1,747 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:36:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 3,220 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:40:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 3,433 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 3,433 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 2,142 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,21:51:45,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 310 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 310 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-12,21:59:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,056 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:00:30,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 8,300 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-12,22:01:59,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,649 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-14,21:41:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Acquires 4,684 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:30:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Biller Registers 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-18,16:36:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,08:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-19,21:26:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 671 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 671 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,21:29:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Biller Sells 1,657 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Biller Sells 1,657 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,21:38:13,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 244 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 244 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-19,22:04:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Surrenders 1,529 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:04:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 2,724 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 1,912 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:09:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:13,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 6,553 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Leiden Surrenders 6,066 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,139 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-19,22:10:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 2,293 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-20,08:00:50,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 4Q 2024 (VRTX)"
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-02-20,17:01:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $407.00 by RBC Capital
VRTX,2025-02-20,20:48:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-24,21:08:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,111 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:01:23,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-25,16:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-25,16:39:26,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:05:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 848 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 848 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:08:20,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Ambrose Sells 884 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Ambrose Sells 884 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:11:09,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 1,767 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:13:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 4,716 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:16:42,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 354 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 354 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-26,21:17:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 9,386 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:19:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 2,470 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-26,21:26:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 3,310 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,15:18:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Tatsis Registers 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-27,15:21:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Atkinson III Registers 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-27,16:24:33,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Business Wire,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Kaftrio(R) (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO(R) in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
VRTX,2025-02-28,12:22:23,57CAAB,Vertex Pharmaceuticals Inc.,100,0.82,products-services,positive,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex Receives CHMP Positive Opinion for Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations >VRTX
VRTX,2025-02-28,21:26:05,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 1,272 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:38:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Atkinson III Sells 2,650 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ambrose Surrenders 1,241 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:42:34,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 7,071 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:43:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Bozic Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:47:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Ceo Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Surrenders 14,079 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:49:45,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"VP Sachdev Surrenders 3,703 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-02-28,21:51:00,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Tatsis Sells 530 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Tatsis Sells 530 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-02-28,22:13:15,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Surrenders 4,962 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-03,21:18:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-04,18:42:35,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-05,21:10:48,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-06,21:10:57,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 4,058 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Business Wire,"Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharmaceuticals Inc.: The deutivacaftor/tezacaftor/vanzacaftor Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-07,15:02:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Tezacaftor/vanzacaftor) is approved in the UK,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces UK MHRA Approval of ALYFTREK(R) (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-03-10,16:45:34,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,17:06:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"CFO Wagner Jr Registers 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,18:00:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Tatsis Registers 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-10,20:05:02,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod,PRESS-RELEASE,GlobeNewswire,CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
VRTX,2025-03-10,20:05:55,57CAAB,Vertex Pharmaceuticals Inc.,100,0.84,products-services,positive,Cervomed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod,NEWS-FLASH,Dow Jones Newswires,CervoMed Announces Positive Results From Extension Phase of Phase 2b Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
VRTX,2025-03-12,20:08:47,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:11:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Tatsis Sells 3,242 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-12,20:12:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Wagner Jr Sells 3,298 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-13,15:12:28,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX",RNS-SEC144,Dow Jones Newswires,"VP Altshuler Registers 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-17,20:09:59,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Altshuler Sells 3,231 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-03-28,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Business Wire,Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Program Updates for Type 1 Diabetes Portfolio
VRTX,2025-03-28,20:49:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-28,21:04:17,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Vertex to Cease Clinical Trials on Diabetes Treatment,FULL-ARTICLE,Dow Jones Newswires,Vertex to Cease Clinical Trials on Diabetes Treatment
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
VRTX,2025-03-31,12:05:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $567.00/Share From $555.00 by B of A Securities
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-04-01,16:09:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $420.00/Share From $408.00 by RBC Capital
VRTX,2025-04-07,16:00:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex: European Commission Approves Expanded Label for Kaftrio,NEWS-FLASH,Dow Jones Newswires,Vertex: European Commission Approves Expanded Label for Kaftrio in Combination With Ivacaftor for People With Cystic Fibrosis >VRTX
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce First Quarter 2025 Financial Results on May 5th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-07,20:11:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
VRTX,2025-04-11,09:30:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Business Wire,"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-11,09:30:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.4,products-services,,Vertex has been awarded the 2025 Canada Gairdner International Award,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis"
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,legal,,Toolgen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom,PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-21,08:00:29,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,"In December 2023, Vertex entered into a licensing agreement with Editas Medicine",PRESS-RELEASE,PR Newswire,ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight
VRTX,2025-04-22,12:02:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,set,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Announced at $535.00/Share by Cantor Fitzgerald
VRTX,2025-04-28,11:00:47,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib,PRESS-RELEASE,GlobeNewswire,Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi(R)) in Patients with Myelofibrosis
VRTX,2025-05-02,13:48:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q EPS $2.49,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Adj EPS $4.06,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 1Q Net $646.3M,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Net $646.3M >VRTX
VRTX,2025-05-05,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports First Quarter 2025 Financial -5-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: First Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.77 billion, a 3% increase compared to Q1 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.24,revenues,down,"Vertex Pharmaceuticals Inc.: Outside the U.S., total revenue decreased 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.54,earnings,down,Vertex Pharmaceuticals Inc.: GAAP net income was $646 million compared to $1.1 billion for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.23,earnings,down,Vertex Pharmaceuticals Inc.: Non-GAAP net income was $1.1 billion compared to $1.2 billion in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex reiterated its guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,Vertex secured European Commission approval for the label expansion of KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 Financial Results
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex recently initiated two Phase 4 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: a Phase 3 study of TRIKAFTA/KAFTRIO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex expects to report results from the Phase 2 study in the second half of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.69,products-services,,Vertex Pharmaceuticals Inc.: The FDA has granted suzetrigine Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.41,products-services,start,"Vertex will initiate a single, adaptive Phase 2/3 trial of povetacicept",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -2-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex expects to complete enrollment in the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,770.2 $ 2,690.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: Net income per common share: Basic $ 2.52 $ 4.26,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -3-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: GAAP net income $ 646.3 $ 1,099.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.61,earnings,positive,"Vertex Pharmaceuticals Inc.: Non-GAAP net income $ 1,054.1 $ 1,241.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Net income per diluted common share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 22,880.5 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -4-
VRTX,2025-05-05,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals First Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports First Quarter 2025 -5-
VRTX,2025-05-05,20:03:58,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX
VRTX,2025-05-05,20:15:16,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 400 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-05,20:45:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-05,21:00:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.65,revenues,up,Vertex Pharmaceuticals 1Q Sales Rise,FULL-ARTICLE,Dow Jones Newswires,"Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge"
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
VRTX,2025-05-06,10:37:10,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $503.00/Share From $550.00 by Leerink Partners
VRTX,2025-05-06,13:23:41,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald
VRTX,2025-05-06,13:49:37,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Neurocrine, and More -- Barrons.com"
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-05-06,14:10:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $515.00/Share From $512.00 by JP Morgan
VRTX,2025-05-06,14:31:37,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-06,15:17:48,57CAAB,Vertex Pharmaceuticals Inc.,91,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, SolarEdge, Vertex, Hims & Hers, DoorDash, Constellation Energy, and More -- Barrons.com"
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-05-06,16:00:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $464.00/Share From $462.00 by Morgan Stanley
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-05-06,16:14:51,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.34,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $442.00/Share From $450.00 by Scotiabank
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-05-06,16:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $423.00/Share From $420.00 by RBC Capital
VRTX,2025-05-06,16:31:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Cantor Fitzgerald each maintained Overweight ratings for Vertex,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com
VRTX,2025-05-06,16:52:29,57CAAB,Vertex Pharmaceuticals Inc.,92,0.61,earnings,positive,Vertex Pharmaceuticals posted first-quarter adjusted profit of $4.06 a share,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Palantir, Tesla, Ford, Constellation Energy, SolarEdge, Vertex, Hims & Hers, DoorDash, and More -- Barrons.com"
VRTX,2025-05-06,20:40:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.77 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks -- IBD
VRTX,2025-05-15,14:39:36,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Altshuler Registers 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-05-15,20:05:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-15,20:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in Upcoming Investor Conferences
VRTX,2025-05-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 1Q 2025 (VRTX)"
VRTX,2025-05-19,20:24:56,57CAAB,Vertex Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Vertex Pharmaceuticals Inc.: the Company is authorized to repurchase up to $4.775 billion,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Files 8K - Other Events >VRTX
VRTX,2025-05-19,20:40:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Vertex Pharmaceuticals Authorizes Additional Buyback,RNS-SEC8K,Dow Jones Newswires,Vertex Pharmaceuticals Authorizes Additional Buyback of Up to $4B
VRTX,2025-05-19,21:08:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Altshuler Sells 52 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Altshuler Sells 52 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:00,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Business Wire,Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.57,products-services,granted,"Deutivacaftor), which is approved in the United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-06,16:00:01,57CAAB,Vertex Pharmaceuticals Inc.,96,0.26,corporate-responsibility,,"Vertex Pharmaceuticals Inc.: In addition, we have established a pilot donation program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents New Data on Benefits of ALYFTREK(R) and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-06-17,15:15:49,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $420.00/Share From $423.00 by RBC Capital
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-06-20,17:45:46,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $460.00/Share From $464.00 by Morgan Stanley
VRTX,2025-06-20,23:15:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Business Wire,Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-20,23:15:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.76,products-services,complete,Vertex Pharmaceuticals Inc.: We are excited to complete enrollment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Business Wire,Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Ono Pharmaceutical and Vertex Announce Strategic Agreement,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Ono and Vertex have entered into an exclusive collaboration,PRESS-RELEASE,Business Wire,Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.39,products-services,,Vertex and Ono Pharmaceutical Announce Strategic Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,08:00:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
VRTX,2025-06-23,11:44:33,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $550.00/Share by HC Wainwright & Co.
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Business Wire,"Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,Vanzacaftor) approved in the EU for people with CF 6 years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-01,11:34:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.57,products-services,granted,European Commission has granted approval for ALYFTREK(R) (deutivacaftor,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces European Commission Approval of ALYFTREK(R), a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-02,20:41:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,insider-trading,,"Coo Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"COO Arbuckle Surrenders 37,243 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Second Quarter 2025 Financial Results on August 4th,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-08,21:20:18,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Second Quarter 2025 Financial Results on August 4th
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-07-14,16:12:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $517.00/Share From $515.00 by JP Morgan
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Canadian News Wire,"Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-07-22,16:55:46,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: The Phase 3 studies in people with CF,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis"
VRTX,2025-08-04,20:01:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Business Wire,Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Announces Results from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q EPS $3.99,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Adj EPS $4.52,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals 2Q Net $1.03B,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Net $1.03B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Business Wire,Vertex Reports Second Quarter 2025 Financial -5-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Second Quarter 2025 Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: Total revenue of $2.96 billion, a 12% increase compared to Q2 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,unchanged,Vertex Pharmaceuticals Inc.: reiterated full year 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,revenues,up,"Vertex Pharmaceuticals Inc.: In the U.S., total revenue increased 14%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.62,earnings,negative,Vertex reported a pre-tax loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: GAAP and non-GAAP net income were $1.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Inc.: Full Year 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Inc.: Total revenue Unchanged,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.57,products-services,granted,"Vertex Pharmaceuticals Inc.: CASGEVY is approved in the U.S., Great Britain, the EU",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 Financial Results
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex is completing Phase 3 studies in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.51,products-services,complete,Vertex has completed enrollment of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -2-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.53,products-services,complete,Vertex has completed the Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.56,earnings,suspended,Vertex Pharmaceuticals Inc.: The company does not provide guidance regarding,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,"Vertex Pharmaceuticals Inc.: Total revenues $ 2,964.7 $ 2,645.6 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -3-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,earnings,,Vertex Pharmaceuticals Inc.: Non-GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Non-GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,-0.65,earnings,negative,Vertex Pharmaceuticals Inc.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,assets,,"Vertex Pharmaceuticals Inc.: Total assets $ 24,036.7 $ 22,533.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -4-
VRTX,2025-08-04,20:01:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,investor-relations,,Vertex Pharmaceuticals Second Quarter 2025 Earnings Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Reports Second Quarter 2025 -5-
VRTX,2025-08-04,20:06:34,57CAAB,Vertex Pharmaceuticals Inc.,93,-0.49,labor-issues,,"Vertex Pharmaceuticals Inc.: the Company announced the retirement of David Altshuler, Executive Vice President and Chief",RNS-SEC8K,Dow Jones Newswires,"Vertex Pharmaceuticals Files 8K - Director, Officer or Compensation Filing >VRTX"
VRTX,2025-08-04,20:13:57,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX
VRTX,2025-08-04,20:15:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX
VRTX,2025-08-04,20:22:21,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex: Announces Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Vertex: Announces Results From Phase 2 Study of VX-993 for the Treatment of Acute Pain
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:30:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:35:36,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex reported adjusted earnings of $4.52 per share,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.64,earnings,up,Vertex Pharmaceuticals Swings to 2Q Profit as,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.61,earnings,positive,Vertex Pharmaceuticals Inc.: The company on Monday posted a profit of $1.03 billion,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,20:45:42,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex backed its revenue outlook,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
VRTX,2025-08-04,21:06:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:21:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,unchanged,Vertex reaffirmed its full-year revenue outlook of $11.85 billion to $12 billion,FULL-ARTICLE,Dow Jones Newswires,"Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update"
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:27:07,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,21:30:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,labor-issues,,Vertex also announced Chief Scientific Officer David Altshuler will retire next August,FULL-ARTICLE,Dow Jones Newswires,Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat -- IBD
VRTX,2025-08-04,23:50:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,00:05:05,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,stock-picks,,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl"
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
VRTX,2025-08-05,11:29:01,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $478.00/Share From $550.00 by HC Wainwright & Co.
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-08-05,11:51:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $439.00/Share From $460.00 by Morgan Stanley
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Stifel
VRTX,2025-08-05,12:22:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.72,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $455.00/Share From $494.00 by Stifel
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
VRTX,2025-08-05,12:42:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.78,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $485.00/Share From $535.00 by Cantor Fitzgerald
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by BMO Capital
VRTX,2025-08-05,13:05:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.58,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $530.00/Share From $557.00 by BMO Capital
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by UBS
VRTX,2025-08-05,13:54:11,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $553.00/Share From $582.00 by UBS
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
VRTX,2025-08-05,14:21:31,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $405.00/Share From $430.00 by RBC Capital
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
VRTX,2025-08-05,15:41:52,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.18,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $442.00 by Scotiabank
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
VRTX,2025-08-05,15:43:12,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $490.00/Share From $520.00 by Truist Securities
VRTX,2025-08-05,20:20:38,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,revenues,,Vertex reported $2.96 billion in second-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat -- IBD
VRTX,2025-08-06,12:30:43,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo
VRTX,2025-08-06,12:30:44,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Maintained With a $460.00/Share by Wells Fargo
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Guggenheim
VRTX,2025-08-06,15:12:04,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $546.00/Share From $558.00 by Guggenheim
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Hold by Canaccord Genuity
VRTX,2025-08-06,18:25:14,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.46,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $411.00/Share From $424.00 by Canaccord Genuity
VRTX,2025-08-07,20:20:46,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sachs Buys 5,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-07,20:24:24,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Kewalramani Buys 10,000 Of Vertex Pharmaceuticals Inc >VRTX"
VRTX,2025-08-19,07:00:40,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)",RNS-SEC13F,Dow Jones Newswires,"Vertex Pharmaceuticals Incorpo, Inst Holders, 2Q 2025 (VRTX)"
VRTX,2025-08-27,13:42:32,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,Dir Bhatia Registers 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-08-29,20:02:38,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bhatia Sells 266 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-09-02,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to,PRESS-RELEASE,Business Wire,Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
VRTX,2025-09-03,17:03:48,57CAAB,Vertex Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Initiated at Market Perform by Raymond James
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Business Wire,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,13:05:01,57CAAB,Vertex Pharmaceuticals Inc.,100,0.4,products-services,,Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Scientists Awarded the 2025 LaskerDeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
VRTX,2025-09-11,14:02:56,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.68,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $475.00/Share From $510.00 by Evercore ISI Group
VRTX,2025-09-23,13:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.49,partnerships,,Vertex Partners with Basketball World Champion Jayson Tatum to,PRESS-RELEASE,Business Wire,"Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX(R), a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain"
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Raised to Outperform From Market Perform by Leerink Partners
VRTX,2025-09-25,11:03:08,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $456.00/Share From $458.00 by Leerink Partners
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:01,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.7,products-services,,Vertex Pharmaceuticals Inc.: Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,,Vertex Pharmaceuticals Inc.: Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3 trial evaluating inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.58,products-services,,Vertex to seek accelerated approval of inaxaplin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:45:04,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Key Advancements Across Kidney Portfolio
VRTX,2025-09-25,11:46:16,57CAAB,Vertex Pharmaceuticals Inc.,100,0.7,products-services,,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept,NEWS-FLASH,Dow Jones Newswires,Vertex Gets FDA Breakthrough Therapy Designation for Povetacicept on IgA Nephropathy >VRTX
VRTX,2025-09-25,12:10:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-09-25,12:25:22,57CAAB,Vertex Pharmaceuticals Inc.,93,0.51,products-services,complete,Vertex also said it completed enrollment for the interim analysis,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
VRTX,2025-10-02,14:42:27,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX,RNS-SEC144,Dow Jones Newswires,VP Biller Registers 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Buy by Citigroup
VRTX,2025-10-02,17:53:04,57CAAB,Vertex Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $575.00/Share From $550.00 by Citigroup
VRTX,2025-10-03,20:13:50,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Biller Sells 694 Of Vertex Pharmaceuticals Inc,FULL-ARTICLE,Dow Jones Newswires,VP Biller Sells 694 Of Vertex Pharmaceuticals Inc >VRTX
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Business Wire,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,earnings,,Vertex to Announce Third Quarter 2025 Financial Results on November 3rd,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-06,20:24:11,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,investor-relations,,Vertex Pharmaceuticals Inc.: The company will host a conference call and webcast at 4:30 p.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
VRTX,2025-10-08,17:58:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Raised to $530.00/Share From $517.00 by JP Morgan
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
VRTX,2025-10-10,17:42:25,57CAAB,Vertex Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals Price Target Cut to $438.00/Share From $439.00 by Morgan Stanley
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:00,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Business Wire,Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.0,products-services,filed,Vertex Pharmaceuticals Inc.: Food and Drug Administration grants rolling review of Biologics License Application for povetacicept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:04:03,57CAAB,Vertex Pharmaceuticals Inc.,99,0.62,products-services,positive,"Vertex Pharmaceuticals Inc.: If positive, the interim analysis",PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
VRTX,2025-10-17,13:05:22,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,filed,Vertex Pharmaceuticals: To Submit First BLA,NEWS-FLASH,Dow Jones Newswires,Vertex Pharmaceuticals: To Submit First BLA Module Before End of Year >VRTX
VRTX,2025-10-17,13:06:39,57CAAB,Vertex Pharmaceuticals Inc.,100,0.41,products-services,start,Vertex Initiates Phase 2b/3 Povetacicept Study,NEWS-FLASH,Dow Jones Newswires,Vertex Initiates Phase 2b/3 Povetacicept Study in Primary Membranous Nephropathy >VRTX
VRTX,2025-10-17,14:04:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-17,14:19:20,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,products-services,,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
VRTX,2025-10-27,20:00:00,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Business Wire,Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-27,20:00:03,57CAAB,Vertex Pharmaceuticals Inc.,100,0.0,marketing,,Vertex to Participate in the UBS Global Healthcare Conference on November 11,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vertex to Participate in the UBS Global Healthcare Conference on November 11
VRTX,2025-10-31,05:30:02,57CAAB,Vertex Pharmaceuticals Inc.,99,0.72,revenues,above-expectations,Vertex Pharmaceuticals Inc.: the company has delivered better-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Vertex Pharma's Stock Has Tumbled. Earnings Will Stop the Pain. -- Barrons.com
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,GlobeNewswire,Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,GlobeNewswire,Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,GlobeNewswire,Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:00,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.4,equity-actions,completed,Vortex Energy Corp.: Completion of the Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-04-24,21:00:01,QVUYTG,Vortex Energy Corp.,99,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,GlobeNewswire,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.4,equity-actions,completed,Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-05-22,22:41:21,QVUYTG,Vortex Energy Corp.,100,0.59,equity-actions,,Vortex Energy Corp.: Prospectus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
VRTX,2025-08-26,12:00:02,QVUYTG,Vortex Energy Corp.,99,-0.61,products-services,,Vortex Energy Corp.: The retrieval of the ANT sensors,PRESS-RELEASE,GlobeNewswire,Vortex Energy Initiates Sensor Recollection at Robinsons River Salt Project Following Completion of ANT Data Collection Phase
